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ABSTRACT OF DISSERTATION

OXIDATIVE STRESS AND PROTEOMIC STUDIES OF MAMMALIAN MODELS
OF AGE-RELATED METABOLIC DYSFUNCTION IN NEURODEGENERATIVE
DISORDERS: (1) UPREGULATION OF PIN1 IN ALZHEIMER MOUSE MODEL
(2) ANALYSIS OF BRAIN POST-INTRANASAL ADMINISTRATION OF INSULIN
IN ALZHEIMER AND INDUCED DIABETIC MOUSE MODELS (3) ANALYSIS OF
PROTEOME CHANGES IN THE PARIETAL LOBULE OF RHESUS MONKEY
NON-HUMAN PRIMATE FOLLOWING RESVERATROL SUPPLEMENTATION
AS A PART OF A WESTERN-DIET

Expression proteomics is the field of science wherein proteins that make
up the cellular proteome are identified both by name and by fold-change.
Depending on the application of proteomics, this change in level could be due to
internal cellular stressors or introduction of xenobiotics. Global oxidative stress
measures use immunohistochemistry to determine the relative level of oxidative
stress of macromolecules within the cell. In this dissertation, both global oxidative
stress measures and expression proteomics were used in a variety of
mammalian models in order to determine the effects of protein upregulation,
intranasal insulin administration, and resveratrol supplementation on the cellular
proteome and the resultant oxidative stress that occurs.
Pin1, a phosphorylation specific peptidyl-prolyl (cis/trans) isomerase that
targets specific effector proteins, has been found to act upon a number of
important proteins identified as contributing towards the progression and ultimate
deterioration seen in AD. Pin1 was selected for viral upregulation in AD mouse
models because of Pin1’s regulatory function in regards to tauhyperphosphorylation and amyloid-precursor protein (APP) processing, and the
fact that it has been shown that Pin1 levels decrease and is oxidatively modified
in brain as AD progresses. In this dissertation study, expression proteomics was
employed after viral upregulation of Pin1 in AD mouse models in order to
observe the changes in protein expression that follow. The findings of this
dissertation study uncover a number of proteins with differential expression as a
function of age following upregulation of Pin1 in an AD model providing evidence
for the possibility of Pin1 being the target of future therapeutics to combat the
progression of AD.
Insulin, while widely being known for its role in the control of blood glucose
levels and cellular energetics, has recently become the focus of interest with
regards to its effect on the brain in neurodegenerative disorders such as AD,

though the downstream effects with respect to changes in the proteome and
oxidative stress levels in AD mouse models remain to be clarified. This
dissertation study focused upon the administration of insulin via the intranasal
route using four mouse models including AD (APP/PS1), induced-diabetes
(dbdb), and the AD/induced-diabetes cross (dbdbxAPP/PS1), and a wildtype
control in order to study the effect of insulin on the brain of these disease state
models with regards to oxidative stress and expression proteomics. The
information garnered from this study suggest a possible beneficial effect, with
regards to protein carbonyl levels, of intra-nasal insulin administration in the AD
mouse models and the cross model, while yielding mixed results for most other
models which may be due to low sample size and internal variability between
animals. Through the use of expression proteomics and Two-way ANOVA,
proteins from many different cellular processes were identified with differential
expression. The results from these dissertation studies shed new light on the
application of intra-nasal insulin to mitigate the effects of AD, a link that has been
shown in recent years.
A diet high in saturated fats and simple sugars, also known as a westerndiet, has been implicated in the progression of metabolic disorders,
cardiovascular disorders, and most recently cognitive disorders. Resveratrol, an
antioxidant that has gained notoriety in the past decade, has been shown to have
beneficial effects with regards to some metabolic disorders, provided the subject
had metabolic disorders to begin with. This dissertation study was focused
around the supplementation of resveratrol into the diets of non-human primate
rhesus monkeys when given a high-fat and sugar diet. The parietal lobule was
selected for examination and expression proteomics employed in order to identify
proteins representative of a wide range of cellular processes as having
differential expression. These identified proteins represent possible routes of
downstream action by resveratrol, as well as display protein level changes simply
through the ingestion of high-fat and sugar diet alone.
KEYWORDS: Alzheimer, Proteomics, Pin1, Insulin, Metabolic disorder, Rhesus
Monkey, Resveratrol
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CHAPTER 1: INTRODUCTION

The studies reported within this dissertation were performed to achieve a better
understanding of the relationship between Alzheimer disease (AD) with an
emphasis on glucose metabolic deficiencies known to contribute to the
progressive neurodegeneration inherent in this disease. By utilizing oxidative
stress measurements and proteomics, a better understanding of the biochemical
relationships between AD and metabolic syndrome has been obtained.
Furthermore, the identification of key brain protein constituents that contribute to
the disease progression may lead to the identification of target proteins for future
therapeutics.

AD and metabolic syndrome, while appearing to be disparate disease states,
share common themes such as increased oxidative stress, neurodegeneration,
altered cellular signaling, and glucose metabolic deficiencies (Butterfield, Drake
et al. 2001, Keeney, Swomley et al. 2012, Barone, Di Domenico et al. 2014,
Luque-Contreras, Carvajal et al. 2014, Tangvarasittichai 2015). To elucidate
information about the progression of AD specifically, both transgenic and knockin mouse models of AD and metabolic syndrome were obtained and the samples
probed for oxidative stress measures and expression proteomics. One protein in
particular that provides regulatory oversight over a large number of cellular
systems, protein interacting with NIMA-1 (Pin1) of the peptidyl-prolyl cis/trans
isomerase (PPIase) class, was specifically upregulated in the AD mouse brain,
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and changes to the global brain oxidative stress and brain proteome were
analyzed.
Intranasal insulin has been the focus of increasing interest due to the finding that
the intranasal route of administration allows insulin access to the brain without
the need to invasively transverse the blood brain barrier (BBB) while also
preventing peripheral insulin-induced blood glucose loss (Henkin 2010). This
finding, coupled with the finding that intranasal insulin has been shown to
improve cognition in humans and rodents, led us to examine the potential
proteomic implications to the treatment (Benedict, Hallschmid et al. 2007). To
study the relationship between metabolic syndrome and AD, a mouse model was
obtained in which diabetes was induced. This mouse was then crossed with an
AD mouse model to provide a novel AD/db mouse to aid in our investigations.
Insulin was administered via the intranasal route over a two-month window and
the mice were harvested. The samples then underwent oxidative stress
measures and proteomics, yielding insights into the means by which insulin may
work as a therapeutic in AD.
While intranasal insulin administration has been shown to be effective in the
treatment of AD, the prevention of the pathology and subsequent clinical
presentation is of utmost importance. The Western-diet (a diet rich in saturated
fat and refined sugar; HFS diet) has been demonstrated to lead to not only
diabetic complications, but also neurodegeneration and a decline in cognitive
function (Myles 2014). Resveratrol (RSV) is a poly-phenolic compound with

2

potential as a therapeutic supplement and has had some success in the
prevention of oxidative stress and treatment of some clinical presentations
associated with neurodegeneration and metabolic syndrome (Bastianetto,
Menard et al. 2015, Szkudelski and Szkudelska 2015). In order to study this link,
brain samples from non-human primates fed an HFS diet were compared to
those fed an HFS diet supplemented with resveratrol emphasizing proteomic
analysis. The results of this project have yielded insights into the potential
proteome changes that resveratrol may induce which provide cellular protection
from damage that accompanies an HFS diet.

In summary, the following hypotheses were addressed in this dissertation
research:
1) Up-regulation of Pin1 in AD mouse models upregulates protective
enzymes and provides protection from oxidative stress.
2) Intranasal insulin administration in AD and obese mouse models
ameliorates oxidative stress and upregulates protective enzymes.
3) Resveratrol supplementation leads to the upregulation of protective
enzymes in brain of Rhesus monkeys raised on high fat and sugar diets
when compared to high fat and sugar diets alone.
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CHAPTER 2: BACKGROUND

2.1 ALZHEIMER DISEASE OVERVIEW
Alzheimer disease (AD) is a neurodegenerative disease that affects a large and
ever growing population of Americans 65 years of age or older, a number that
current estimates place at approximately 5.1 million and which may grow to over
20 million by the year 2050 due to an aging Baby Boomer population (Hebert,
Scherr et al. 2003). Classically, AD has been linked to a loss of synapses, an
increase in the number of extracellular β-amyloid plaques formed from the
amyloidogenic processing of amyloid precursor protein (APP), as well as an
increase in intracellular neurofibrillary tangles (NFTs) composed of aggregated
hyperphosphorylated Tau, a microtubule stabilizing protein (Katzman and Saitoh
1991). In the last decade or so, strong evidence has emerged linking AD to an
increase in oxidative stress due in part to both the increased production of
reactive oxygen and nitrogen species (ROS and RNS respectively) as well as a
loss of function of many antioxidant defense enzymes (Butterfield 1997,
Markesbery 1997, Aksenov, Tucker et al. 1998, Munch, Schinzel et al. 1998,
Butterfield, Howard et al. 1999, Koppal, Drake et al. 1999, Markesbery and
Carney 1999, Varadarajan, Yatin et al. 1999, Butterfield and Kanski 2002,
Sultana, Piroddi et al. 2008).
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2.1.1 ALZHEIMER DISEASE STAGING

AD is clinically characterized by a decline in episodic memory that is often
mistaken for normal cognitive deficiencies due to aging. Because the pathology
remains hidden within the patient’s brain tissue, clinical diagnosis during the
earlier stages of the disease is a process that remains inherently error-prone and
subjective, though advances have been made in which to aid a physician in
making a correct diagnosis (Waldemar, Phung et al. 2007, Mattila, Koikkalainen
et al. 2011). A diagnosis of AD is established using the guidelines set by the
National Institute of Neurological and Communicative Disorders and Stroke and
the AD and Related Disorders Association (NINCDS-ADRDA). Using these
guidelines, both possible as well as probable AD are diagnosed using cognitive
exams and neuroimaging methods that attempt to differentiate between normal
aging, patients with non-AD dementia, and AD. To date, physicians have access
to an array of tools designed to help with diagnosis such as the Mini Mental State
Evaluation (MMSE), which is used to track a patients cognitive prowess (a 30
point scale is used with greater than 25 being normal and less than 25 as
probable AD), and also imaging alternatives such as MRI and PET scans that
help visualize both the potential hippocampal, sulci, and gyri degeneration as
well as glucose utilization (Folstein, Folstein et al. 1975, de Leon, George et al.
1983, Jack, Petersen et al. 1999, Sultana and Butterfield 2010). More recently
much research has been conducted in search for a viable blood or cerebral
spinal fluid (CSF) biomarker that would allow for early non-subjective detection
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(Aluise, Sowell et al. 2008, Trojanowski, Vandeerstichele et al. 2010, Sultana,
Mecocci et al. 2011).

Typical AD can be classified into four main stages: Pre-clinical AD (PCAD), mild
cognitive impairment (MCI; most often amnestic MCI or aMCI), early-AD (EAD)
and late-stage AD (LAD). PCAD is defined as the stage of AD in which the
patient presents as a fully cognitive, non-AD patient on cognitive instruments
such as MMSE, yet the growing pathology within the brain tissue is present yet
likely unknown precluding early death from a non-neurodegenerative means
(Small, Fratiglioni et al. 2001, Sperling, Aisen et al. 2011). aMCI has been
described as being the transition stage between normal cognition and EAD, and
is able to be subdivided into both aMCI and non-amnestic-MCI, the former of the
two presenting with memory deficits and demonstrates a 10-15% conversion rate
per year to AD (Petersen 2000, Petersen 2004, Sultana and Butterfield 2010).
Pathologically, each stage differs in that both amyloid plaques as well as NFTs
increase in distribution and density from MCI to LAD, though non-demented
individuals also are known to possess both types of pathology while maintaining
normal cognition (Tremblay, Pilote et al. 2007). Through use of imaging
techniques such as MRI, all three stages of clinical AD described demonstrate
varying degrees of degeneration, with MCI presenting only a small amount of
degeneration affecting the hippocampus, sulci, and gyri whereas a much larger
degree of neurodegeneration affecting the same brain regions in LAD as well as
an additional atrophy of the frontal lobe and ventricular widening is observed in
EAD and LAD (Drayer, Heyman et al. 1985, Jack, Petersen et al. 1999, Farrow,
6

Thiyagesh et al. 2007). Additionally, research conducted using positron-emission
tomography (PET) scans concluded that regional glucose utilization within the
brain, including the temporal lobe, was significantly reduced in AD patients, a
trend that was shown to remain true for possible PCAD and MCI patients,
indicating a severe energy deficiency as glucose is known to be the predominant
source of energy for brain tissue (de Leon, George et al. 1983, Herholz, Salmon
et al. 2002, Chetelat, Desgranges et al. 2003, Chetelat, Eustache et al. 2005,
Petrie, Cross et al. 2009).

The employment of redox proteomics has given substance to these claims as our
laboratory has shown that vital glycolytic enzymes have become oxidatively
modified with a reduced activity that may account for or at least contribute to a
loss of metabolic activity as observed by PET scans (Castegna, Aksenov et al.
2002, Butterfield, Galvan et al. 2010).

2.1.2 AMYLOID BETA AND OXIDATIVE STRESS

AD is histopathologically characterized by the presence of abnormal protein
deposits, including senile plaques (rich in amyloid β-peptide [Aβ]) and
neurofibrillary tangles (NFT, rich in hyperphosphoryalted tau) (Selkoe 2001), and
synaptic loss. Structural MRI studies demonstrate early brain atrophy in AD that
is predominant in hippocampus, precuneus, temporal and parietal lobes, parts
of the frontal cortex and cingulate gyrus. In contrast, the cerebellum typically
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displays minor, if any, changes in AD brain compared to controls (Fox, Crum et
al. 2001).

A number of hypotheses have been proposed to link the pathologic lesions,
neuronal histopathology, biochemistry, and clinical symptoms of AD, including
the amyloid cascade, excitotoxicity, oxidative stress, and inflammation
hypotheses. All these hypotheses are based, to some extent, on the role of Aβ.
The oxidative stress hypothesis for the pathogenesis and progression of AD
(Markesbery 1997, Butterfield, Drake et al. 2001, Butterfield, Reed et al. 2007) is
based on the observations of increased cellular free radical production in AD.
Such production is proposed to exceed the capacity to scavenge or otherwise
neutralize these damaging moieties, leading to neuronal dysfunction and death
that is mediated by protein oxidation/nitration and lipid peroxidation (Butterfield
DA 1997a).
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Figure 2.1.2: PICTORIAL DEPICTION OF AMYLOIDOGENIC AND NONAMYLOIDOGENIC PROCESSING

The Aβ-induced oxidative stress hypothesis in AD (Markesbery 1997,
Butterfield, Drake et al. 2001) is supported by Aβ-induced elevation of oxidative
stress markers in brain, and subsequent neuronal degeneration (Frautschy, Baird
et al. 1991). Senile plaques are composed of a core of Aβ surrounded by
degenerating neurites. Aβ is derived by the proteolytic cleavage of amyloid
precursor protein (APP) by action of β- and γ-secretases. Both Aβ(1-40) and
Aβ(1-42) peptides, among other Aβ peptides, are found in human brain and
the former two are the most abundant forms of this peptide. Aβ exists in at least
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four aggregated states: monomers, oligomers, protofibrils, and fibrils. Recent
data suggest that oligomeric Aβ is the toxic species of this peptide rather than
Aβ fibrils themselves (Glabe 2005). Previous studies (Butterfield and BoydKimball 2005, Butterfield, Reed et al. 2007, Sultana and Butterfield 2010) have
identified the single methionine residue at position 35 of Aβ(1-42) as a critical
mediator of increased oxidative stress and neurotoxic properties of this peptide.
Recent in vivo from our laboratory showed for the first the time methionine is
critical to induce oxidative stress and consequently, a key player in amyloid βinduced oxidative stress and AD pathogenesis (Sultana and Butterfield 2010,
Sultana, Robinson et al. 2012).

2.1.2.1 AMYLOID BETA PEPTIDE

It has long been established that the role of oxidative stress in AD is a critical to
the damage of vital cellular components such as proteins, lipids, and nucleic
acids (Halliwell and Gutteridge 1984, Markesbery and Lovell 2006, Butterfield,
Bader Lange et al. 2010, Weidner, Bradley et al. 2011). This damage if left
unchecked is a primary reason for the eventual degeneration of neurons,
possibly through both apoptotic means and necrotic means (Butterfield,
Castegna et al. 2002). The Aβ-induced oxidative stress hypothesis proposed by
our laboratory and others (Markesbery 1997, Butterfield, Drake et al. 2001),
states that Aβ and the damage it initiates are the principal means underlying this
injurious increase in oxidative stress observed in AD brain.
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As discussed above, APP may be processed into two major isoforms of Aβ by
way of β- and γ-secreteases; Aβ(1-40) and Aβ(1-42). Studies have demonstrated
that as AD progresses, the levels of Aβ(1-40) in CSF remains relatively constant,
while in contrast, levels of Aβ(1-42) in CSF decrease but levels of Aβ(1-42)
increase in senile plaques (Tamaoka 1998). This distribution has been attributed
to the possibility of an efflux deficiency for Aβ(1-42) which may play a role in
plaque formation (Gustafson, Skoog et al. 2007, Owen, Sultana et al. 2010).
Previously, plaques were perceived to be the primary pathogenic element of AD,
yet more recently evidence provided insights into the notion that plaques may be
an extra-cellular storage site for cells to deposit excess Aβ, suggesting the real
damaging agent, may be a much smaller aggregate form of Aβ(1-42) oligomers
(Walsh and Selkoe 2004, Glabe 2005). Research has shown that while plaques
do not correlate with cognitive dysfunction in AD, soluble oligomers do (Tomic,
Pensalfini et al. 2009). More recently, researchers have discovered in AD that
distinct assemblies of Aβ oligomers impair cholinergic neurotransmission and
long-term potentiation associated with learning and memory (Li, Jin et al. 2011,
Bao, Wicklund et al. 2012).

The Aβ-induced oxidative stress hypothesis places the majority of the causative
effect of increased cellular oxidative stress upon oligomeric Aβ(1-42), as it is
believed that only these hydrophobic oligomers are viable to insert into the lipid
bilayer wherein they may form alpha-helices to begin the proposed catalytic ROS
production that may lead to the lipid peroxidation and protein oxidation found in
AD (Butterfield, Swomley et al. 2013).
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While studies have found that oligomeric Aβ(1-42) correlates with increased
oxidative stress, the exact method by which this occurs is still under debate
(Tomic, Pensalfini et al. 2009). Strong evidence has been put forth by our lab and
others that implicates the methionine-35 (Met-35) residue of Aβ(1-42) in the
process of ROS generation. Since Aβ(1-42) is cleaved from APP, a
transmembrane protein, our laboratory proposed that Aβ(1-42) oligomers are
capable of re-entering the lipid bilayer where they may adopt an alpha-helical
structure. In doing so, Met-35 would interact with the carbonyl of Ile-31 according
to the i+4 rule of alpha-helices (Kanski, Aksenova et al. 2002). It is hypothesized
that because the oxygen of the Ile-31 carbonyl group is more electronegative
than the sulfur of Met-35, the electron density of the lone pairs of electrons are
drawn away from the sulfur nucleus of Met-35 and are primed for oxidation by an
extrinsic factor.

Once the Aβ oligomers insert into the bilayer, the hydrophobic environment lends
itself towards the stabilization of a one-electron oxidation of an already primed
Met to the sulfuranyl free radical [MetS+] (Varadarajan, Kanski et al. 2001,
Butterfield and Kanski 2002). It is this sulfuranyl free radical that is hypothesized
as being the initiator in a series of free radical chain reactions that take place
within the lipid bilayer that generate lipid peroxidation products and oxidatively
modified membrane proteins (Butterfield and Kanski 2002, Butterfield and
Sultana 2011). Substitution of amino acids in critical positions within the Aβ(1-42)
peptide negate the injurious effects of Aβ(1-42). For example, the substitution of
Gly with Asp at residue 37 of Aβ(1-42) imparts a negative charge to the Aβ(1-42)
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peptide that excludes the peptide from the lipid bilayer (Kanski, Aksenova et al.
2002). Another substitution that replaces Ile-31 with the known α-helix breaker,
proline, again alleviates oxidative stress induced by peptide, consistent with our
hypothesis that the α-helical structure of Aβ(1-42) in the lipid bilayer is important
for the production of oxidative stress (Kanski, Aksenova et al. 2002).

Transgenic Caenorhabditis elegans that express human Aβ(1-42) demonstrated
increased oxidative stress that was nullified by the substitution of Met-35 with
another sulfur containing amino acid, Cys, in an attempt to demonstrate the
differences in chemistry of the two sulfur atoms and their associated residencies
(thioether vs. thiol) (Yatin, Varadarajan et al. 1999). In an in vitro study, Met-35 in
Aβ(1-42) was substituted by norleucine, i.e., a methylene moiety for the S-atom
of Met, to produce [Aβ(1-42)M35NLE]. This substitution produced a mutant
peptide with an amino acid of similar length and hydrophobicity as the original
Met-35. Aβ(1-42)M35NLE was unable to induce toxicity through oxidative stress
by way of free radical generation (Yatin, Varadarajan et al. 1999, Clementi,
Pezzotti et al. 2006, Dai, Sun et al. 2007, Murray, Bernstein et al. 2009).

The J20 mouse, which is a transgenic mouse with human APP containing
Swedish (KM670/671NL) and Indiana (V717F) mutations, showed elevated Aβ(140/42) deposition and increased oxidative stress in brain (Robinson, Lange et al.
2011). Introduction of a third mutation to APP, Met631Leu, corresponding to the
Met-35 residue of Aβ(1-42), resulted in no oxidative stress in brain of these mice
at 9 months of age (Sultana and Butterfield 2010). This result demonstrated in
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vivo in a mammalian model what had been seen earlier in a worm model: Met-35
of Aβ(1-42) is essential for oxidative stress in vivo in AD models, and presumably
in AD brain as well.

Important to note are other findings that provide evidence contrary to the Met-35
centric hypothesis such as research conducted that used Aβ(25-35) instead of
Aβ(1-42) with a substitution of Met-35 with norleucine at the c-terminal position
that did not abrogate the oxidative induced by the peptide (Pike, WalencewiczWasserman et al. 1995). These data, however, should be read with the
understanding that a C-terminal Met displays altered chemistry from a Met within
the α-helix (Varadarajan, Kanski et al. 2001).

2.1.2.2 OXIDATIVE STRESS

The oxidation of proteins by reactive oxygen species (ROS) within a cell has long
been linked with not only the normal aging process (Harman 1956, Agarwal and
Sohal 1996, Hohn, Konig et al. 2013), but also with a multitude of diseases that
range from cancer (Ma, Zhang et al. 2013, Yang, Chay et al. 2013) to
neurodegenerative diseases such as AD (Aksenov, Aksenova et al. 2001, Reed,
Pierce et al. 2009, Di Domenico, Coccia et al. 2011). As with other posttranslational modifications (PTMs) of proteins, the oxidation of a peptide chain,
indexed mostly by elevated protein carbonyls or 3-nitrotyrosine, may alter the
three-dimensional conformation of the peptide resulting in a gain or loss of
function. While ROS has been shown to play a much larger cellular role in both
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signaling and anti-microbial defense when tightly regulated by functioning ROSscavenging mechanisms, a loss of such scavenging mechanisms or an
unhealthy increase in the cellular oxidants result in damage that takes the form of
protein, lipid, and nucleic acid oxidation (Markesbery and Lovell 1998, Aksenov,
Aksenova et al. 2001, Butterfield, Reed et al. 2006, Markesbery and Lovell 2006,
Perluigi, Di Domenico et al. 2010, Weidner, Bradley et al. 2011).

Protein oxidation refers to the direct or indirect damage afflicted to a protein
during the process of an oxidative insult. There are four major forms of protein
oxidation that are detectable by standard methods; these being protein
carbonylation, protein nitration, protein bound-lipid peroxidation products, and
protein glycation end-products.
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Figure 2.1.2.2: OXIDATIVE STRESS DIAGRAM
(Permission granted by Elsevier)

When ROS such as O2-., H2O2, or .OH act directly upon a protein, protein
carbonylation is a result, often forming reactive aldehydes or ketones by way of
primary or a secondary mechanisms (Suzuki, Carini et al. 2010, Cabiscol,
Tamarit et al. 2014). Primary protein carbonylation may occur via alpha-carbon
hydrogen extraction, oxidation of the peptide backbone resulting in
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fragmentation, and oxidation of amino acid side chains. Protein carbonylation
normally refers to the reactive ketones or aldehydes that are formed as a product
of direct free radical induced damage of proteins and can affect both the protein
backbone as well as the side chains (Stadtman and Levine 2000). Direct protein
carbonylation may result in the loss of function of the affected protein (Smith,
Carney et al. 1992, Levine 2002). Primary protein carbonylation would be difficult
to detect if not for the use of 2,4-dinitrophenylhydrazine (DNPH) that forms
hydrazones that are detectable through immunochemical blotting (Levine,
Williams et al. 1994, Suzuki, Carini et al. 2010). While many forms of protein
oxidation are irreversible barring clearance from the cell, protein carbonylation
may be remedied by carbonyl reductase. Protein carbonyls may be more than
just cell stressors as new information points to protein carbonyls as a potential
form of redox signaling through a reversible enzyme mediated system (Wong,
Marcocci et al. 2010, Wong, Bansal et al. 2012).

What is sometimes called “secondary protein carbonylation” is an indirect method
of protein oxidation in that an intermediate molecule carries the initial free-radical
product to the protein which then initiates the protein carbonylation adduct
(Grimsrud, Xie et al. 2008, Suzuki, Carini et al. 2010). The brain is especially
susceptible to the effects of lipid peroxidation due to the high concentrations of
iron, high oxygen utilization, and high polyunsaturated fatty acids (PUFA) density
(Reed, Pierce et al. 2009). One method for the initiation of lipid peroxidation
occurs when a carbon centered radical is produced on a polyunsaturated fatty
acid (PUFA) by the abstraction of an allylic hydrogen by some form of radical
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present within the bilayer, for example the Met-35 resultant sulfuranyl radical of
Aß1-42. Paramagnetic O2, which lacks a dipole moment, diffuses into the lipid
bilayer where it may react with the carbon centered radical to form a lipid peroxylradical (Butterfield, Castegna et al. 2002, Shichiri 2014). The lipid peroxyl-radical
may then abstract an allylic hydrogen from an adjacent poly-unsaturated lipid
which propagates the chain reaction and forms a lipid peroxide which may then
undergo cleavage forming an array of possible reactive aldehydes such as F2isoprostane, 4-hydroxy-nonenal (HNE), and 2-propen-1-al (acrolein). HNE, for
example, is primarily produced from arachidonic acid, an omega-6 PUFA with
inflammatory and signaling properties of its own and is found in high
concentrations within the lipid bilayer of the brain (Butterfield, Bader Lange et al.
2010). This binding of an amphiphilic lipid moiety to a protein may induce a
denaturing conformational change that is responsible for loss of function detected
in samples with high levels of protein bound lipid peroxidation products (Sayre,
Zelasko et al. 1997, Subramaniam, Roediger et al. 1997, Lovell, Xie et al. 2001,
Sultana and Butterfield 2004) Other PUFAs that are of importance in the
generation of lipid peroxidation products are linoleic acid (LA), docosohexenoic
acid (DHA), among others (Shichiri 2014). While reactive aldehydes are a main
by-product of lipid peroxidation, other deleterious effects such as loss of lipid
asymmetry and apoptosis may follow (Bader Lange, St Clair et al. 2010).
Reactive aldehydes have been found to deplete the cell of nucleophilic
compounds that serve as antioxidants (GSH, lipoic acid, thioredoxin) by
covalently modifying proteins via Michael addition in a secondary protein
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carbonylation reaction (Yang, Wu et al. 2004). Protein-bound and free reactive
aldehydes are being investigated as potential markers of oxidative stress and
disease progression in conditions ranging from neurodegeneration to brain
infarction (Igarashi and Kashiwagi 2011, Lee, Wong et al. 2012). While one result
of lipid peroxidation is protein modification, the products of lipid peroxidation
themselves are potentially dangerous due to their electrophilic nature as well as
their tendency to act as oxidants (Morrow and Roberts, 2002).

Protein nitration occurs following formation of peroxynitrite (ONOO-) from
superoxide (O2.-) and nitric oxide (NO.) interacting. The latter molecule, nitric
oxide (NO.), is a molecular radical and important second messenger produced
from L-argenine using one of three nitric oxide synthase (NOS) variants, is vitally
important in some biological pathways such as vasodilation, inflammation, and
immune response (Nelson, Connolly et al. 2003, Calabrese, Cornelius et al.
2009, Shahani and Sawa 2011). High concentrations of NO., through secondary
reactions with ROS, may go on to produce other reactive nitrogen species
(RNS), such as NO2, N2O3, and ONOO-. These compounds react with the metal
cofactors of enzymes, the peptide backbone, and specific amino acids such as
tyrosine, cysteine, and tryptophan which are generally more readily modified by
nitrosative stress (Stamler 1994). Peroxynitrite, in the presence of CO2, is known
to covalently modify tyrosine residues to produce 3-nitrotyrosine (Butterfield and
Kanski 2001, Butterfield, Reed et al. 2007). The formation of 3-nitrotyrosine has
been found to inactivate key proteins such as actin, manganese superoxide
dismutase (MnSOD), copper/zinc superoxide dismutase (Cu/Zn SOD), and
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tyrosine hydroxylase. Due to the steric constraints placed on the OH functionality
of tyrosine residues by the addition of a large nitro group in the 3’ position,
difficulty in phosphorylating the tyrosine, via tyrosine kinases, may occur
(Butterfield DA 1997a). Research on aging rats has shown that nitrated tyrosine
residues may play an important role in the aging process, as protein nitration
levels increase with age in the cerebellum, substantia nigra, hippocampus,
semimembranosus and soleus muscle, as well as localized to membrane raft
proteins that may play a significant role in cell signaling processes (Dremina,
Sharov et al. 2005, Fugere, Ferrington et al. 2006, Poon, Calabrese et al. 2006,
Gokulrangan, Zaidi et al. 2007).

Methionine has been found to be exceptionally prone to oxidation in vivo when
exposed to high levels of oxidative stress, resulting in the sulfoxidation products
Met-sulfoxide [Met(O)] and Met-sulfone [Met(O2)] (Moskovitz, Maiti et al. 2011).
While the Met-sulfone is generally an irreversible product of sulfoxidation, Metsulfoxide, may yet be converted back to Met via the methionine-sulfoxide
reductase (Msr) pathway (Oien and Moskovitz 2008). Sulfoxidation has been
implicated in aging disorders such as AD, in which a large percentage of Aβ in
amyloid plaques has been found to contain the sulfoxide modification on Met35
(Kuo, Kokjohn et al. 2001, Boutte, Woltjer et al. 2006). In fact, the highly reactive
nature of Met35 in Aβ is of such importance, that, as noted above, it is the central
theme within the Aβ induced oxidative stress hypothesis, put forth by our
research group (Varadarajan, Yatin et al. 1999, Sultana and Butterfield 2010,
Butterfield and Sultana 2011).
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2.2 PIN1

Proline is an amino acid that may adopt one of two spatial conformations within a
peptide. These two conformations are referred to as cis and trans
orientations, of which the isomerization between the two is known to be a slow
step in protein folding. Pin1, or Protein Interacting with NIMA (never in mitosis-A),
is a PPIase (peptidyl-prolyl cis/trans isomerase) of the parvulin subfamily that
specifically acts upon protein substrates with the motif of phosphorylated Ser/Thr
on the amino- terminal side of an adjacent Pro (pSer/Thr-Pro) (Lu, Hanes et al.
1996).

Our group demonstrated that not only was Pin1 oxidatively modified in age
matched control AD hippocampus, but that the activity as well as the protein
expression of Pin1 were both found to be significantly reduced (Sultana, BoydKimball et al. 2006). The implications of this finding are vast when considering
the large amount of literature that links Pin1 as a crucial regulator of intracellular
processes. When considering AD, Pin1 has been shown to regulate both directly
and indirectly amyloid precursor protein (APP) and Tau, the proteins of which
constitute the primary components of the neuropathological hallmarks β-amyloid
plaques and NFTs, respectively. In normal brains, Pin1 has been shown to
induce dephosphorylation of Tau at key sites via regulation of protein
phosphatase 2-A (PP2A), and consequently the knock down of Pin1 leads to
hyper-phosphorylation and aggregation of Tau positive NFTs (Ma, Pastorino et
al. 2012).
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Figure 2.2: PIN1 CIS VS TRANS SPACIAL CONFIGURATION
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Interestingly, Pin1 has been shown to act on the intracellular C-terminal domain
(AICD) pT668-P of APP to direct processing of this protein toward the nonamyloidogenic pathway (Pastorino, Sun et al. 2006). More recently, it has been
found that Pin1 interacts with and inhibits the kinase activity of glycogen
synthase kinase 3-β (GSK3β) that has been implicated in both Tau
hyperphosphorylation as well as directing APP toward the amyloidogenic
pathway (Ma, Pastorino et al. 2012). The discovery that Pin1 both directly
associates with the protein precursors to the classical AD pathological hallmarks
as well as the protein kinase systems that contribute to this pathology, illustrates
not only the complex and integral control that Pin1 exerts over this system, but
also the potential ramifications that an oxidized and dysfunctional Pin1 could
have.

2.2.1 PIN1 IN AD/MCI

In normal non-neuronal cells, the means in which cells divide is through the
induction of the cell cycle creating two daughter cells from one parental cell. This
process may be classified into four distinct segments (G1, S, G2, M); two growth
phases G1 and G2, which themselves are built around an S phase during which
DNA is replicated, followed by the M phase, or mitosis, which consists of
chromosomal as well as cellular separation into two distinct daughter cells. In an
effort to control abnormal proliferation of cells through the different phases of the
cell cycle, regulatory points exist that the cell must fulfill for division to
proceed. These checkpoints exist between the phases and are maintained by
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numerous control proteins. Neurons in a typical non-disease brain of an adult
remain in what is called a quiescent state (the Go phase) wherein the cell cycle
has been halted. Neurodegenerative diseases in which the protein Tau is key
demonstrate aberrant cell cycle reentry of quiescent neurons and has been
shown to proceed through multiple cell cycle check points, yet ultimately failing to
complete mitosis, and proceeding to apoptosis.

To date, a large number of control proteins important to the cell cycle have been
identified as having aberrant expression, localization, or posttranslational
modifications in AD (Bonda, Lee et al. 2010, Keeney, Swomley et al. 2012).
Moreover, cell cycle proteins have been found to have irregular expression in
earlier stages of AD. Our group reported that levels of CDK2, CDK5, and cyclin
G1 were elevated in both the hippocampus and IPL in brains of subjects with
aMCI, demonstrating that cell cycle changes may appear prior to the classical AD
diagnosis (Sultana and Butterfield 2007, Keeney, Swomley et al. 2012).

While induction of neurons into the cell cycle by ambiguous means has been shown
to be characteristic of AD, the progression and ultimate failure of the neuron to
complete the cell cycle remains to be clarified in its own right, possibly due to the vast
complexity of cell cycle control. Interestingly, not only does Pin1 interact with and
promote cell cycle entry, but Pin1 has also been found to be associated with a
number of proteins fundamental to the progression and completion of the cell cycle;
associations that could have disastrous effects in vivo due to deficient expression or
oxidized Pin1.
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Pin1 has been found to regulate the tumor suppressor p53, a protein of significance
in controlling cell proliferation, through multiple mechanisms including increasing
p53 stability through the interaction of p53 with the E3 ubiquitin ligase murine
double minute-2 (Mdm-2), facilitating the DNA binding of p53 to a number of proapoptotic promoter sites under conditions of cellular stress, enhancing p53
acetylation by p300 or CREB response binding protein (CBP) acetylases, and the
dissociation of p53 from the inhibitor of apoptosis-stimulating protein of p53
(iASPP), which is a key inhibitor of p53 (Mantovani, Tocco et al. 2007). In addition
to p53, Pin1 has been implicated as a crucial player in the regulation of
phosphorylated retinoblastoma protein (pRb), a key mediator of the G1/S phase
transition. Evidence demonstrates that Pin1 plays a crucial role in the association
of pRb with CDK/Cyclin complexes and release of E2F transcription factors
important for entry into the S-phase (Rizzolio, Lucchetti et al. 2012). Pin1 has
been shown to directly affect the stability of the cell cycle inhibitor p27kip1 via
interaction with the SCFskp2 (skp, cullin, F-box containing complex) E3 ubiquitin
ligase complex (Zhou, Yang et al. 2009).

The finding of an oxidized and dysfunctional Pin1 makes a significant contribution
to the two-hit hypothesis of AD proposed by Zhu et al., providing a direct link in
which increased oxidative stress in conjunction with cell cycle abnormalities play
vital roles in AD pathogenesis (Zhu, Raina et al. 2004)
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2.3 RESVERATROL AND RHESUS MONKEY PARIETAL LOBE

The Western diet has been under much scrutiny in the past two decades due to
the abundance of saturated fat and refined sugar (HFS) content commonly used
in food preparation. Long term HFS consumption has been linked to a number of
physiological conditions such as obesity, insulin resistance and type-2 diabetes
mellitus, cardiac disease, ischemia, cancer, and cognitive dysfunction (Myles
2014). The projected costs of obesity-related diseases is not only measured in
monetary terms but also in life-years used to treat the disease and life-years lost
to early death associated with obesity. While much research has been completed
in uncovering the effects of chronic obesity on the endocrine and circulatory
systems, there is still much to learn about the effects of obesity and the role it
plays in cognitive decline. It has been long thought that cognitive dysfunction is
directly tied to chronic metabolic low grade inflammation and vasculitis that
accompanies obesity.

Resveratrol (RSV) is a polyphenol found primarily in skins of red grapes,
blueberries, cranberries, nuts such as peanuts and pistachios, as well as in
cocoa. RSV has garnered widespread acclaim due to the many studies that link
RSV to beneficial effects, such as neuroprotection, anti-inflammation, regulation
of metabolic pathways and improvement of glucose tolerance, and its use as an
antioxidant (Carrizzo, Forte et al. 2013, Bastianetto, Menard et al. 2014,
Szkudelski and Szkudelska 2014, Poulsen, Fjeldborg et al. 2015). The mode of
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action for RSV appears to be its indirect activation of the NAD+-dependent
deacetylase, sirtuin-1 (SIRT1), possibly through the inhibition of cyclic AMP
(cAMP)-degrading phosphodiesterase, that leads to the deacetylation of the p65
subunit of NF-κB (Howitz, Bitterman et al. 2003, Blander and Guarente 2004,
Dai, Kustigian et al. 2010, Park, Ahmad et al. 2012).

While much research has been conducted on RSV in a number of scenarios and
models, a proteomic analysis of the primate brain when subjected to differing
diets has yet to be shown. This dissertation study aimed to fill that gap by
comparing and contrasting the proteome of Rhesus monkey parietal lobe, raised
on three different diets: a control diet, a HFS diet, and a HFS+RSV diet. The
parietal lobe of the brain is primarily responsible for the integration of sensory
information, both tactile and perceived, as well as spatial recognition and the
processing of language. Impairments to the parietal lobe are seen in a number of
neurodegerative diseases such as AD, Parkinson disease, and amyotrophic
lateral sclerosis (Cosottini, Pesaresi et al. 2012, Teixeira, Machado et al. 2014,
Brickman, Zahodne et al. 2015). By gaining insights into the proteome changes
associated with the diets and the influence of RSV, better understanding of the
mechanisms associated with RSV protection from obesity-related diets has
emerged.
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CHAPTER 3: EXPRESSION PROTEOMICS OF PIN1 OVEREXPRESSION IN
APP/PS1 ALZHEIMER MODEL KNOCK-IN MOUSE BRAIN VIA ADENOASSOCIATED VIRUS
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3.1 STUDY OVERVIEW
The peptidyl-prolyl-(cis/trans)-isomerase (PPIase) PIN1 has been associated
with the major pathological hallmarks of Alzheimer disease (AD) progression
such as amyloid precursor protein processing, tau-phosphorylation state, and cell
cycle control. Here, we used an adeno-associated-virus (AAV) to upregulate
PIN1 production in an APP/PS1 AD mouse model while using a GFP control.
Using expression proteomics, a number of proteins were identified as presenting
with differential levels resulting from PIN1 upregulation, important to multiple
cellular subsystems such as energy production, structural integrity, and signaling.

3.2 INTRODUCTION
Alzheimer disease (AD) is a degenerative neurological condition that impairs
memory and cognitive function primarily in seniors, yet has been found to be
distinguishable from the normal aging process. Though the primary cause of AD
is heavily debated, there are fundamental consistencies in pathological hallmarks
that exist in AD such as Amyloid-beta-42 (Aβ-42) plaques and oligomers as well
as neurofibrillary tangles (NFTs) of the cytoskeletal protein Tau (Pastorino, Sun
et al. 2006, Balastik, Lim et al. 2007). While Aβ-42 and Tau have received the
majority of the attention of AD researchers, the role of the cell cycle and its
regulatory processes have begun to appear to be key players as well in the
progression of AD (Bonda, Lee et al. 2010, Keeney, Swomley et al. 2012, Lin, Li
et al. 2015). Though these pathological hallmarks and processes may appear
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disparate, the peptidylprolyl-(cis/trans)-isomerase (PPIase) PIN1 (proteininteracting-with-NIMA (Never-in-mitosis-A)-1) has been found to be intricately
involved in what appear to be all major areas affected by AD and thus warrants
further investigation (Wulf, Liou et al. 2002, Butterfield, Abdul et al. 2006,
Pastorino, Sun et al. 2006).
PIN1 primarily functions as a regulator of proteins, utilizing its PPIase function to
activate target proteins through the mechanical means of proline cis/trans
isomerization (Zhou, Lu et al. 1999). PIN1, unlike many other PPIases, is
phosphorylation specific and primarily recognizes the target protein amino acid
motif of pSer/pThr-Pro. While the isomerization of this bond may produce drastic
structural rearrangements, it also has the effect of modifying the availability of
targeted phosphorylation site to the cytosol, and subsequently, to phosphatases.
Because of this, PIN1 has been likened to an intracellular protein clock, or timer,
by altering the time-frame a protein may be activated/inactivated through
phosphorylation (Lu, Finn et al. 2007). PIN1 often times acts upon multiple levels
of a signaling network, as evidenced in its role in amyloid precursor protein (APP)
processing as PIN1 both works directly upon APP as well protein kinases and
phosphatases such as CDK-5 and PP2A that phosphorylate and
dephosphorylate APP, respectively (Butterfield, Abdul et al. 2006).
The intricate control that PIN1 has over the many processes that go awry in AD
is only compounded by the fact that PIN1 is both oxidatively damaged and its
levels are significantly decreased in AD brain, as was evidenced by work from
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our laboratory and those of our collaborators (Sultana, Boyd-Kimball et al. 2006,
Chen, Li et al. 2015).
Here, we used an adeno-associated-virus to upregulate levels of PIN1 in an AD
mouse model in an attempt to replenish or even protect against the eventual loss
of basal PIN1 levels that accompanies AD progression. Utilizing expression
proteomics, we have identified a number of proteins found to have differential
levels when compared to GFP controls that these identified proteins may play
important protective roles, due to the expansive control that PIN1 exerts over the
cell. We expect these findings to be important contributions to the understanding
of what we believe to be a critical regulatory protein impaired during AD.

3.3 MATERIALS AND METHODS
3.3.1 ANIMALS
The mouse models used in this experiment were genotyped and obtained from
the Michael P. Murphy laboratory at the University of Kentucky, Lexington KY.
For use in the experiments performed, four distinct mouse models were used:
APPΔNL/ΔNL/PS1P264L/P264L (APP/PS1) were used for both groups (control; GFP:
and experimental; Pin1). The mice were housed in an AALAC-approved animal
facility with a 12-hour light-dark cycle and fed the standard rodent chow ad
libitum. Prior to any experiment involving the use of animal models, University of
Kentucky (UK) IACUC approval was obtained and all work herein was performed
in accordance with all federal specifications.
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All animals were subjected to IACUC approved wellness checks regularly and
throughout the duration of the study timeframe. Any animal deemed unfit to
continue the study due to perceived suffering was immediately euthanized.
3.3.2 VIRAL UPREGULATION OF PIN1 AND GFP
APP/PS1 mice were bred from a set of two breeders. Upon birth, the mouse
pups were anesthetized on ice inside an insulating pouch until immobile, where
they were individually taken and injected in the temporal lobe with 2 µL of either
AAV with PIN1 or GFP. The mice were closely watched for complications and
separated by gender at 3 weeks.
3.3.3 SAMPLE PREPARATION
The brains from the mice were thawed and individual homogenates were
prepared using a wheaton glass homogenizer (approximately 40-45 passes) with
ice-cold isolation buffer [0.32M sucrose, 2mM EDTA, 2mM EGTA, 20mM HEPES
buffer, 0.2µg/ml PMSF, 4µg/ml leupeptin, 4 µg/ml pepstatin, 5µg/ml aprotinin].
Homogenates were subsequently vortexed followed by sonication on ice for 10s
at 20% power, two times, allowing the sample to rest 20s on ice between
vortexings, with a Fisher 550 Sonic Dismembrator (Pittsburgh, PA, USA).
Concentration of the protein in the homogenates was determined by the Pierce
BCA method (Rockford, IL, USA).
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3.3.4 PIN1 OVEREXPRESSION VALIDATION
In order to validate the efficacy of the injections, a western blot of Pin1 levels as
compared to GFP controls (1 month, 6 month, 9 month, and 12 month) was
conducted using western-blot analysis and an anti-Pin1 antibody (Santa Cruz,
CA, USA). The Pin1 levels were standardized to internal standard tubulin levels
using an anti-tubulin antibody raised in goat (Santa Cruz, Ca, USA).

3.3.5 TWO-DIMENSIONAL POLYACRYLAMIDE GEL ELECTROPHORESIS
(2D-PAGE)
3.3.5.1 ISOELECTRIC FOCUSING
Brian tissue homogenates (200 µg) were shaken in 200 µl of rehydration buffer
[8M urea, 2.0% (w/v) CHAPS, 2 M thiourea, 50 mM dithiothreitol (DTT), 0.2%
biolytes, 0.01% bromophenol blue] for 1.5 hr at RT followed by sonication for 10
s at 20% power. The sonicated samples were applied to 11 cm pH 3-10
ReadyStripTM IPG strips with a linear gradient. IPG strips were actively
rehydrated at 20°C for 18 h at 50 V using a Bio-Rad Protean IEF Cell (Hercules,
CA, USA). After 60 min, 2 mL of mineral oil was added to the strips to prevent
dehydration. After 18 hours, isoelectric focusing was performed at a constant
temperature of 20 °C starting at 300 V for 2 h, 500 V for 2 h, 1000 V for 2 h, 8000
V for 8 h, and finishing at 8000 V for 10H. The IPG strips were then removed
upon cycle completion and stored at -80°C immediately following removal and
stored until future use.
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3.3.5.2 SDS PAGE
IPG strips of Pin1 and GFP samples were first thawed for 10 min followed by 4
ml of a DTT-containing equilibration buffer [50 mM Tris-HCl, pH 6.8, 6 M urea,
1% (w/v) SDS, 30% v/v glycerol, 0.5% DTT] for 10 minutes in the dark. The strips
were then removed from the solution and placed in clean plastic wells where 4
mL of an iodoacetamide-containing buffer [50 mM Tris-HCl, pH 6.8, 6 M Urea,
1% (w/v) SDS, 30% v/v glycerol, 4.5% iodoacetamide] was added in the dark.
The IPG strips were rinsed in a 1x dilution of TGS running buffer and placed into
Criterion precast linear gradient (8-16%) Tris-HCl polyacrylamide unstained gels.
Precision Plus ProteinTM All Blue molecular weight marker was added and
agarose gel was overlaid. Pin1 and GFP Gels were run at a constant voltage of
200 V for approximately 60 min using 1x Tris/Glycine/SDS running buffer.
3.3.5.3 IMAGE ANALYSIS
Spot intensities of the Pin1 and GFP imaged unstained gels were quantified by
densitometry using PDQuest 2-D Analysis Software (Bio-Rad, Hercules, CA,
USA). Individual gel spot intensities were normalized to the total density of the
individual gel. Spot densities from the two experimental groups at each time point
(GFP: 1 month, 6 month, 9 month, 12 month; Pin1: 1 month, 6 month, 9 month,
12 month) were compared and the spots with a statistically significant difference
based on two-way ANOVA and Bonferonni multiple comparisons were
considered for in-gel trypsin digestion and identification of the protein of interest.
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3.3.5.4 SYPRO RUBY STAINING
Following 2D-PAGE, and PDQuest analysis, sample gels (Criterion precast
linear gradient (9-16%) Tris-HCl polyacrylamide gels) were run rollowing the
same procedure but fixed in solution [7% (v/v) acetic acid, 10% (v/v) methanol]
(50 mL) for 45 min at RT on a gently orbiting platform. After fixing, the solution
was removed and 50 mL of Sypro Ruby® Protein Gel Stain was added to stain
proteins in the gel overnight (15 h) at RT with gentle orbiting. Gels were rinsed
and transferred to 50 mL of deionized water at RT until scanning. The Gels were
scanned utilizing a Bio-Rad ChemiDocTM XRS+ imaging system (Hercules, CA)
and subsequently stored in deionized water at 4°C until extraction of protein
spots.
3.3.5.5 IN-GEL TRYPSIN DIGESTION AND PEPTIDE EXTRACTION
Pin1 and GFP protein spots were identified as significant utilizing PDQuest
software and excised from 2D-gels followed by transfer to Eppendorf microcentrifuge tubes. 20 μL of 0.1 M ammonium bicarbonate (NH4HCO3) were added
to the tubes and allowed to incubate at RT for 15 min. Then, 30 μL of acetonitrile
were added to each tube and again, incubated at RT for 15 min. The solvent was
then removed and the gel plugs were allowed to dry at RT for 30 min. 30 μL of 20
mM DTT in 0.1 M ammonium bicarbonate was added to the gel plugs and
incubated for 45 min at 56°C. After the removal of the DTT/NH4HCO3 solution, 30
μL of 0.05 M iodoacetamide (IA) in 0.1 M NH4HCO3 were added and incubated at
RT for 15 min. The IA solution was removed and 150 μL of 0.05 M NH4HCO3
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were added to incubate for 15 min at RT. 200 μL of acetonitrile (CAN) were then
added to the solutions and incubated for another 15 min. Gel plugs were dried for
30 min at RT before rehydrating with 10 μL of modified trypsin solution in 0.05 M
NH4HCO3. Plugs were incubated at 37 °C and shaken at 230 RPMs overnight
(15 hrs.). The digested solution was transferred into Eppendorf tubes while 20 μL
of a 5% CAN, 0.1% formic acid (FA) solution was added to the old tube
containing the gel plug and sonicated in a RT water-bath for 15 min. Following
water-bath sonication, 30 μL of a 95% CAN, 0.1% FA and 0.001 M NH4HCO3
solution were added and water-bath sonicated for 15 min. The solution was then
removed from the gel plug tube and combined with the supernatant digest
solution. Using a Speed-Vac, the digest solution samples were concentrated to a
volume of 10 μL. C18 ZipTips were used to remove salts and contaminants from
the trypsin-digested peptide solution using the following procedure. 10 μL of
100% CAN were aspirated into the ZipTip and expelled 5 times, followed by 10
μL of a 50% CAN solution containing 0.1% FA, which were aspirated and ejected
5 times. The trypsin digested solution was drawn and pushed out of the miceocolumn a total of 10 times to allow for peptide adherence to the column.
Contaminants were eliminated from the peptides in the ZipTip by washing with 10
μL of a 5% CAN and 0.1% FA solution by aspirating and expelling the eluent 5
times. The end result samples were stored at -80 °C until MS/MS analysis.

36

3.3.5.6 NANOLC-MS WITH DATA DEPENDENT SCAN
The Pin1 and GFP samples were analyzed by a nanoAcquity (Waters, Milford,
MA)-LTQ Orbitrap XL (Thermo Scientific, San Jose, CA) system in a datadependent scan mode. A packed capillary column (0.1 x 130 mm column packed
with 3.6 μm, 200 angstrom XB-C18) and a gradient with 0.1% FA and CAN/0.1%
FA at 200 nL/min were used for separation. The MS spectra were acquired by an
orbitrap at 30,000 resolution and MS/MS spectra of the six most intense ions in
the MS scan were attained by the orbitrap at 7,500 resolution. The resultant data
files from each sample were then searched against the most current version of
the Swiss-Prot database by SEQUEST (Proteome Discoverer v1.4, Thermo
Scientific). A minimum of two high-confidence peptide matches were required for
protein identification (false discovery rate <1%). Proteins that are matched with
the same peptides are reported as one protein group. Resultant MS/MS data
were first verified by a comparison of the expected molecular weight and
isoelectric point of the identified protein to that of the extracted plug from the 2-D
gel.
3.3.6 ONE-DIMENSIONAL POLYACRYLAMIDE GEL ELECTROPHORESIS
(1D-PAGE)
Brain homogenates (50 μg) of Pin1 or GFP samples were suspended in 4x
sample loading buffer [0.5 M Tris, pH 6.8, 40% glycerol, 8% SDS, 20% βmercaptoethanol, 0.01% Bromophenol Blue] and diluted to 1x with deionized
water. Samples were heated at 95 °C for 5 min in a hot water-bath, then cooled
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on ice, and loaded into a CriterionTM precast (4-12%) Bis-Tris polyacrylamide 18
well gel with Precision Plus ProteinTM All Blue Standards. Gels were run at RT in
a Criterion CellTM vertical electrophoresis buffer tank (Bio-Rad, Hercules, CA,
USA) containing a 1x dilution of XT MOPS running buffer at 80 V for 15 min. The
voltage was subsequently increased to 120 V for the duration of the
electrophoretic run (~100 min).
3.3.6.1 1D-WESTERN BLOTTING
Proteins from the gel were transferred to a nitrocellulose membrane (0.2 nm)
using a Trans-Blot TurboTM Blotting System (Bio-Rad, Hercules, CA, USA).
Following transfer, membranes were placed in a blocking solution of 3% bovine
serum albumin (BSA) in Wash Blot [150 mM NaCl, 3 mM NaH2PO4, 17 mM
NaHPO4 and 0.04% (v/v) Tween 20] at RT for 1.5 h. Pin1 was detected with
polyclonal primary antibodies raised in rabbits (1:8000 dilution in blocking
solution). The blots were incubated at RT with rocking for 2 h. The membranes
were then rinsed three times in Wash Blot (5 min, 5 min, 10 min), followed by a 1
h incubation with rabbit horseradish peroxidase (1:3000) secondary antibody at
RT with gentle rocking. Blots were rinsed three times (5, 10, and 10 min) in Wash
blot and developed by chemiluminescence using ClarityTM Western ECL
Substrate. After developing for 5 min at RT in the dark, blots were scanned using
a Bio-Rad ChemiDocTM XRS+ imaging system and quantified using Image LabTM
software (Bio-Rad, Hercules, CA, USA). The membranes were rinsed with Wash
Blot for 5 min, two-times, and stripped with RE-Blot Plus Strong solution for
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exactly 10 min at RT, followed by three 5 min rinses with Wash Blot. The
resultant membranes were then blocked once again in 3% BSA for 1.5 h. Then,
anti-tubulin antibodies raised in mice (1:20000) were added to the Wash Blot
solution for 2 hours at RT. Membranes were washed and incubated with a
secondary HRP-conjugated antibody, washed, developed colorometrically, and
scanned as previously described.
3.3.7 STATISTICAL ANALYSIS
An ANOVA was performed and followed by a Bonferroni correction in order to
correct for multiple comparisons in order to determine the effects of Pin1 overexpression on the expression of pin1-target proteins within the tissue of the
APP/PS1 mouse brain as a function of age. An α<0.05 was selected as a
measure of significance for the ANOVA while a p<0.05 was selected as a
measure of significance for the multiple comparisons test. Fold-change values of
the differentially expressed proteins were then determined by dividing the
average spot intensity of the gels from the GFP or Pin1 groups by the average
spot intensity of the gels of the GFP group within an age group. Proteins that
were identified by the SEQUEST search algorithm with p<0.01 were considered
to be statistically significant. To validate MS/MS identification of the significant
differentially expressed proteins, the position of protein spots on the 2D-gel
images were first examined to confirm that they were located near the expected
molecular weight and isoelectric point values from the SwissProt database
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information.

3.4 RESULTS
3.4.1 PIN1 EXPRESSION ANALYSIS
In order to first determine if the injections of AAV containing PIN1 to brain was
successful, western-blot analysis was performed using an anti-Pin1 antibody. At
one month, PIN1 was found to be approximately 3.5-fold higher levels than the
GFP control (p<0.01), the 6-month group showed just under 3.0-fold higher levels
than the GFP control (p<0.0002), the 9-month group displayed again, nearly 3.5fold higher levels of PIN1 than the GFP group (p<0.1), and finally the 12-month
group was found to be over 7-fold higher levels of PIN1 than the GFP control
(P<0.0002). Using these findings, we feel confident that the injections of PIN1
were successful in their over-expression of PIN1 protein in the APP/PS1 mouse
brain, while the GFP control did not.

In order to determine the overexpression of Pin1 samples, only the Pin1 samples
showing overexpression were used for the analysis. Because the injection of
AAV showed no signs of success or failure until post-mortem analysis, it is
assumed that the virus injection was only successful in those samples showing
drastic up-regulation of Pin1 protein levels.
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Figure 3.4.1a 1-month Pin1 Expression (p<0.01) a. Tubulin b. Pin1
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Pin1 Expression 7 Month
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Figure3.4.1b: 6-Month Pin1 Expression (p<0.0002) a. Tubulin b. Pin1
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Pin1 Expression 9 Month
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Figure 3.4.1c: 9-Month Pin1 Expression (p<0.01) a. Tubulin b. Pin1
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12 Month Pin1 Levels
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Figure 3.4.1d: 12-Month Pin1 Expression (p<0.0002) a. Tubulin b. Pin1
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3.4.2 PROTEOMICS ANALYSIS
Proteomic analysis of the proteins of the Pin1 vs GFP groups were conducted
using a 2D-PAGE approach with Sypro Ruby staining. Protein spot intensities
were compared between these eight groups to determine differentially expressed
proteins. Figure 3.4.2 shows representative examples of 2-D gel images of the
isolated proteins from the brain of the Pin1 vs GFP mouse model by the average
spot intensity of the GFP gel spots with respect to age. For example, a fold
increase of 1.50 in the Pin1 12-month age group represents a 50% increase in
protein expression of the 12-month age group with respect to the group used as
a control. A fold value less than 1, denotes a decrease in protein expression, for
example a fold of 0.5 represents a decreased protein expression of 50%.

As shown in Tables 3.4.2, the proteins were identified by more than one peptide
sequence. Furthermore, proteins that were identified by MS/MS analysis were
first validated by visually comparing the known molecular weight and isoelectric
point provided by Sequest software to the relative position of extracted protein
spot on the gel. Table lists the 10 significant differentially expressed proteins
identified in the comparison of the Pin1 and GFP mouse models were:
Neurofilament light polypeptide:1609 (↑2.1-fold, p=0.02, 12MP v 12MG),
Immunity-related GTPase Family Q protein:1616 (↑3.3-fold, p=0.03, 12MP v
12MG), Phosphatidylethanolamine-binding protein-1:2106 (↑98.6-fold, p=0.02,
1MP v 1MG), Myc box-dependent-interacting protein 1:3106 (↑1.7-fold, p=0.09*
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(T-test, not significant but trending), 9MP v 9MG), Actin-related protein-3:3513
(↑2.1-fold, p=0.03, 9MP v 9MG), D-dopachrome decarboxylase:4007 (↑1.9-fold,
p=0.04, 9MP v 9MG), Growth factor receptor-bound protein 2:4201 (↑0.21-fold,
p=0.0007, 9MP v 9MG), Glycerol-3-phosphate dehydrogenase:6302 (↑2.1-fold,
p=0.01 9MP v 9MG), Carbonic Anhydrase:5312 (↑3.5-fold, p=0.002, 9MP v
9MG), Cofilin 1:8109 (↓0.52-fold, p=0.35*(Ttest, not significant but worth
mentioning), 6MP v 6MG). Representative gels are shown below.
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Table 3.4.2: Pin1 v GFP Protein Identification
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Figure 3.4.2a Neurofilament Light Chain level vs time
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Figure 3.4.2b IRGq level vs time
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12 Month

2106 ‐ PEBP1
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Figure 3.4.2c PEBP1 level vs time
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Figure 3.4.2d Mycbox dependent interacting protein 1 level vs time
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3513 ‐ ARP3
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Figure 3.4.2e ARP3 level vs time
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Figure 3.4.2f D-Dopachrome decarboxylase level vs time
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4201 ‐ GRBP2
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Figure 3.4.2g GRBP2 level vs time
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Figure 3.4.2h Carbonic Anhydrase 2 level vs time
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6302 ‐ G3PD
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Figure 3.4.2i G3PD level vs time

8109 ‐ Cofilin‐1
1800000
1600000
1400000
1200000
1000000
800000
600000
400000
200000
0
1 Month

6 Month
G

9 Month
P

Figure 3.4.2j Cofilin-1 level vs time
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12 Month

Figure 3.4.2k: Representative Excision Gels Pin1 vs GFP
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3.5 DISCUSSION OF RESULTS
As mentioned, Pin1, has been implicated as an important mediator of many of
the major AD pathological hallmarks (Lu, Wulf et al. 1999, Butterfield, Abdul et al.
2006). Pin1 is a peptidyl-prolyl cis/trans isomerase that specifically functions on
pin1 protein targets with a phosphorylated-ser/thr n-terminal to a proline motif in
order to enact a three-dimensional configurational rearrangement which imparts
a function change for the target protein (Lu, Wulf et al. 1999). Moreover, Pin1 has
been found interact with both amyloid precursor protein and protein tau directly,
and indirectly through the modification of protein kinases and phosphatases (Lu,
Wulf et al. 1999, Zhou, Kops et al. 2000, Ma, Pastorino et al. 2012). Our
laboratory has shown in the past that Pin1 is both oxidatively modified as well as
decreased in level in AD (Sultana, Boyd-Kimball et al. 2006). This decrease likely
results in aberrant effector protein activity which would likely have far reaching
consequences in protein activity and even expression given Pin1’s role as a cell
cycle regulator (Wulf, Liou et al. 2002). More recently, we found that the active
site of Pin1, Cys-113, is oxidatively modified which impedes its catalytic activity
and therefore, function (Chen, Li et al. 2015). Our hypothesis throughout the
current dissertation study was that through the upregulation of Pin1 protein levels
by way of a vector, protein expression would be altered and proteins with
protective effects with respect to AD progression would be upregulated.

3.5.1 PIN1 PROTEIN LEVELS
To determine the effects of AAV up-regulation of Pin1 in APP/PS1 AD mice, first
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it must be shown that the viral upregulation of Pin1 protein took place. Figure
3.4.1a shows that even at one month, Pin1 levels were increased at
approximately 3.5-fold levels of that of the GFP controls. The trend continued
with the 6-month age group as figure 3.4.1b depicts with a 3.0-fold increase in
Pin1 protein levels. Figure 3.4.1c shows that at 9 months Pin1 protein levels
were again, 3.5-fold higher than GFP controls and at 12 months, Figure 3.4.1d
demonstrates that Pin1 levels were approximately 7-fold higher than that of the
GFP controls. It should be noted here, that the 12-month age group was injected
first so as to let those mice begin aging. Because they were the first group, the
injections were not as effective as those of the other age groups, therefore in
these calculations the mice that showed no noticeable increase in Pin1 over GFP
were excluded and it was assumed that the injections failed as all other mice
injected displayed drastic increases in Pin1 production. However, for the duration
of the oxidative stress measurements, all samples were included despite their
corresponding Pin1 levels in order to ensure a rigorous testing and that faith in
the results would be assured.

3.5.2 EXPRESSION PROTEOMICS
Pin1 is a complex regulatory protein, playing roles in many subcellular systems
such as immunity, cell cycle control, transcription, as well as apoptosis and
cellular damage response (Yaffe, Schutkowski et al. 1997, Winkler, Swenson et
al. 2000, Zhou, Kops et al. 2000, Ryo, Nakamura et al. 2001, Wulf, Ryo et al.
2001, Butterfield, Abdul et al. 2006). Therefore, it is important to investigate the
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downstream effects and protein levels that may be impacted by Pin1
upregulation, as the artificially increased levels may have unanticipated
widespread effects, be they beneficial or detrimental to the health of the cell. To
this end, discovery based expression proteomics was employed to investigate if
the upregulation of Pin1 protein levels impacted the levels of any other proteins
significantly altered.

After a rigorous two-way ANOVA, 8 proteins were found to have a significant
differential expression (2 proteins either close to significance or presenting
interesting trends were also included) with Pin1 upregulation when compared to
GFP controls (Table 3.4.2). These proteins, described in detail below, are
representative of many different subcellular systems including energy production,
cellular signaling, transcription control, immune response, and cellular structure.

Neurofilament-light (NFL) is an intermediate filament vital to the overall structure,
growth, and plasticity of the neuron. One of the first cytoskeletal aberrations
presented in the neocortex in AD is the alteration of NF triplet proteins in
amyloid-beta plaques that are associated with dystrophic neurites (DNs).
Recently, it has been shown that the deletion of NFL in the APP/PS1 mouse
model contributes to DN pathology and amyloid-beta deposition, as well as
microgliosis and synapse degradation (Fernandez-Martos, King et al. 2015).
Moreover, Cdk-5 a ser/thr proline-directed kinase that Pin1 directly acts upon,
interacts with neurofilaments in order to regulate and dynamically control axonal
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cytoskeletal outgrowth important to synapse formation and dendritic plasticity
(Kesavapany, Li et al. 2003). Neurofilament health and functionality is a vital
component to a functionally healthy neuron. In the present study, it is shown that
at 12 months, NFL is 2.1-fold higher in the Pin1 treated mice than the GFP
control mice, indicating that Pin1 may be playing a protective role through direct
action or indirect Cdk-5 modulation. We posit that the upregulation of Pin1 in this
instance is potentially preserving some synaptic functionality and dendritic
plasticity over that of GFP control, though further analysis is needed to confirm.

Immunity related GTPase family Q protein (IRG-Q) is part of a family of proteins
that comprise of an early immune response and, in most cases, a result leading
to the clearance of pathogens. In the current study, IRG-Q was found to be 3.3fold increase in the Pin1 overexpressed mice than that of GFP mice. It would be
tempting to say that the vector used to deliver the Pin1 overexpression may have
caused this increase, though it is not seen nearly as high in the GFP control
group which used the same vector for overexpression; therefore, it can be
concluded that this increase in IRG-Q is a result of pin1 overexpression itself.
Pin1 has been known to function in the immune response and diseases that
affect the immune system from the regulation of HIV-1 lifecycle, to interaction
with Toll-like receptors and their downstream signaling effects (Tun-Kyi, Finn et
al. 2011, Hou, Wang et al. 2015). With regards to the current study, it has been
found that loss of Irg1 results in the activation of effector proteins that damage
lysosomal function (Maric-Biresev, Hunn et al. 2016). Further evidence suggests
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that Irg’s affect autophagy and proteasome function through association with
Atg5 and Atg8 (Haldar, Piro et al. 2014). Upregulation of Irg protein levels may
indicate an attempt by the cell to focus on the clearing of amyloid beta from the
cell by way of autophagy and the ubiquitin proteasome.

Phosphatidylethanolamine-binding protein 1 (PEBP1), also known as Raf kinase
inhibitor protein (RKIP) is part of a highly conserved signaling family of proteins
that are involved predominantly in the cellular cycle and in brain development
(Vallee, Coadou et al. 2003). RKIP is intricately involved in the MAP kinase and
NF-kappaB pathways through the interaction of MEK and Raf-1 inhibition and
TAK1, NIK, IKK-alpha/beta inhibition, respectively (Yeung, Rose et al. 2001,
Corbit, Trakul et al. 2003). Antagonism of the NF-kappaB pathway would provide
a means for the cell to decrease inflammatory response, neuro-inflammation
being an important hallmark of AD progression (Alam, Alam et al. 2016). Here,
we show that RKIP is 98.6-fold increased in the Pin1 overexpressed mice when
compared to the GFP mice. RKIP has also been found to associate with and
activate choline acetyl transferase (ChAT), which creates acetylcholine (Sun, Luo
et al. 2013). Acetylcholine is a neurotransmitter found to have low levels in the
synapses of frontal cortex in Alzheimer disease patients. In order to correct for
this, acetylcholine esterase inhibitors were used to combat the symptoms of AD
with limited success (Mendiola-Precoma, Berumen et al. 2016). Through RKIP
overexpression, it appears that the cell may be attempting to rectify this situation
through activation of ChAT though acetylcholine levels should be checked in the
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future to verify this notion.

Myc box-dependent-interacting protein 1 (BIN1) is a nuclear localized isoform of
amphiphysin 2 initially shown to interact with myc to suppress its tumor
promoting effects (Sakamuro, Elliott et al. 1996). Early drosophila studies
demonstrate that amphiphysin isoforms localize in membrane domains
undergoing drastic changes in cell curvature or surface area expansion, thus its
role in actin cytoskeleton integrity was confirmed (Zhang and Zelhof 2002). More
recently however, amphiphysin isoforms have been described in the trafficking of
vesicles and endosome budding events for intracellular trafficking through its
interaction with SNX4, a process of great importance to all cell types, but brain
tissue in particular (Zhang and Zelhof 2002). SNX molecules have been
implicated in the association with transmembrane receptors such as EGF, insulin
receptors, leptin receptors, and PDGF, and is suspected to be complicit in the
selection of vesicular cargo or the budding event in particular. Much more
recently, it has been shown that Bin1 loss and dysfunction raise amyloid-beta
generation through the increase in APP and BACE1 interaction in early
endosomes (Ubelmann, Burrinha et al. 2016). The APP and BACE1 now trapped
in dysfunctional endosomes may no longer be recycled in the axon and continue
to produce amyloid-beta which are not able to be cleared to lysosomes
(Ubelmann, Burrinha et al. 2016). In the present study, we have shown BIN1 to
be increased 1.9-fold in the Pin1 overexpressed mice as compared to control,
though this finding is not statistically significant (p=0.09) due to a large standard
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deviation among samples. It was included, however, due to the fact that near
significance was obtained and this protein plays a vital role in a process known to
go awry in neurodegenerative diseases such as AD. AD is plagued with not only
synaptic vesicle dysfunction, but also intracellular trafficking dysfunction due to
aberrant endosomal trafficking. We posit that increased Bin1 in the Pin1 mice
represent an attempt to rescue early endosome function to prevent amyloid-beta
propagation and endosomal obstruction.

Another protein intricately involved in cell structure and integrity is actin-related
protein 3 (ARP3) which when in combination with seven other proteins,
comprises of the ARP2/3 complex involved in the nucleation of actin filaments
(Pollard, Blanchoin et al. 2000). Moreover, ARP2/3 complex binds to already
existing actin networks in order to catalyze the formation of branched filaments, a
vital component of the dendritic nucleation model (Pollard, Blanchoin et al. 2001).
In regards to the neuronal axonal growth cone, ARP2/3 is a vital component to
plasticity and works in conjunction with cofilin to provide properly functioning
neuronal networks, an area severely and detrimentally impacted in AD (Dumpich,
Mannherz et al. 2015, Jang and Chung 2016). Within the current study, ARP3
has been shown to be 2.1-fold (p=0.056) increased in the Pin1 overexpressed
group over that of the GFP control. An increase in ARP3 may represent an
attempt by the cell to maintain control over its axonal growth cone and neuronal
plasticity in order to protect the functional synapses that remain in AD state,
considering that the ARP2/3 complex is highly associated with synaptic plasticity
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as it has been found to be present in dendritic formation and synaptic integrity
and the axonal growth cone (Dumpich, Mannherz et al. 2015). Since synaptic
degradation and axonal/dendritic shortening is known to occur in AD, any attempt
to mitigate this damage would potentially serve to protect the brain from further
degeneration (Mitsuyama, Futatsugi et al. 2009).

D-dopachrome decarboxylase (tautomerase) D-DT is an cytokine that is related
to the macrophage migration inhibitory factor (MIF) super-family of proteins, in
both sequence and catalytic activity (Honigman, DiGregorio et al. 2012). MIF
proteins are generally described pro-inflammatory cytokines with control over the
innate and adaptive immune response, with specific activation of the MAP kinase
cascade and interestingly, as an immunosuppressive agent against
glucocorticoids and in some cell types acts as a survival or anti-apoptotic protein
factor (Merk, Mitchell et al. 2012). D-DT binds MIF cell surface receptor complex
CD74/CD44 where it proceeds to act as an effector for cell signaling activity. It
has been shown that neutralization of MIF/D-DT in vivo decrease inflammation
and improves outcome in some animal models of disease, where MIF/D-DT have
been found to be elevated (Merk, Mitchell et al. 2012). Here, we find that D-DT is
increased 1.9-fold in the Pin1 upregulated mice in comparison to that of the GFP
controls. This upregulation of this newly described cytokine could be indicative of
a cellular response initiated to combat inflammation described in AD models, and
potentially to prevent loss of brain tissue through necrotic or apoptotic means
through the induction of pro-survival pathways (Capsoni, Brandi et al. 2011).
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Growth factor receptor-bound protein 2 (Grb2), is required for nearly all receptor
tyrosine kinase signaling cascades, and was first described in the MAPK
pathway as a mediator between MAPK and the epidermal growth factor receptor
(EGFR) (Belov and Mohammadi 2012). Grb2 itself lacks most canonical
enzymatic functions, but instead relies on its physical association with receptor
SH2 domains to recruit further effector proteins to localized regions for signal
transduction. Because of the ubiquity of Grb2 in RTK singal transduction, it is
difficult without extensive signaling workups to determine the effect in these
samples of an upregulated Grb2. Here we find that Grb2 is 2.1-fold increase in
the Pin1 overexpressed mice as opposed to the GFP controls. Grb2 association
is linked to the activation of the Ras-MAPK and PI3-Akt pathways (BoriackSjodin, Margarit et al. 1998). Both pathways are pro-survival pathways indicating
that the observed increase in Grb2 could potentially be associated with the cell
attempting to preserve itself. Moreover, Grb2 has been implicated as not only a
docking protein, but also a trafficking protein. In an AD-like model, it has been
shown that Grb2 interacts with the AICD of APP and co-localized in mature
autophagasomes, indicating that Grb2 may be working to effectively clear APP in
a healthy cell, and that the upregulation of Grb2 in the current study may indicate
that the brain is working to prevent amyloid buildup through the degradation of
the precursor or AICD remnants (Roy, Chakrabarti et al. 2014).

Energy production is an area severely impacted by AD as shown in PET imaging
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of Alzheimer brain (Zippo and Castiglioni 2016). Our laboratory, and others, have
shown numerous energy related proteins to be either deficient in level or
oxidatively damaged throughout the disease progression (Butterfield, Hardas et
al. 2010). One such protein is glycerol-3-phosphate dehydrogenase (GPDH), a
lesser known enzyme involved in metabolism and lipid synthesis that links
respiration to synthesis. At its most basic function, GPDH oxidizes glycerol-3phosphate (the alcohol version of glyceraldehyde-3-phosphate) to
dihydroxyacetone phosphate (DAP), a glycolytic intermediate, using an FADH2
electron transfer intermediate for reduction (Mracek, Drahota et al. 2013). GPDH
is highly specific to tissue type (presenting mostly in brown adipose tissue,
muscle, and brain) and its expression is suppressed in most tissue types and
varies with energy demands (Benard, Faustin et al. 2006). Moreover, GPDH
functions as an important step in the glycerophosphate shuttle which links
glycolysis to fatty acid oxidation and oxidative phosphorylation (Green, Needham
et al. 1937). Interestingly however, the upregulation of GPDH may be a doubleedged sword, in that the cell may benefit from increased or more efficient energy
production and lipid synthesis, but at the cost of increased ROS production due
to the Flavin dependent electron transfer intrinsic to GPDH (Mracek, Drahota et
al. 2013). Here, we show that GPDH levels are 2.1-fold (p=0.05) that of the GFP
controls when Pin1 levels are increased. This result could possibly be indicative
of an attempt by the cell to recover control over energy production though in
doing so may possibly be exacerbating the ROS problem inherent in AD model
mice.
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Carbonic anhydrase is a zinc metalloenzyme which functions to catalyze the
reversible hydration of carbon dioxide to bicarbonate, mutations of which in the
brain may cause cerebral calcifications and is often a contributor to mental
deficiencies (McMahon, Will et al. 2001, Kida, Palminiello et al. 2006). Carbonic
anhydrase also functions through the interaction with Na+/H+ exchanger,
substituting intracellular proton for an extracellular sodium ion (Counillon and
Pouyssegur 2000). Through this interaction along with its named function,
carbonic anhydrase II expands its function to that of pH equilibrium,
gluconeogenesis, lipogenesis, bone resorption and calcification, and
cerebrospinal fluid formation (Kida, Palminiello et al. 2006). It was shown that in
developing human brain deficient of carbonic anhydrase II, cerebral calcifications
could be detected using computed tomography scanning within the sulci and in
the putamen and caudate (Cumming and Ohlsson 1985). Here, carbonic
anhydrase II is shown to be 3.5-fold higher (p=0.004) in the Pin1 overexpressed
mice than that of the GFP mice. This increase in brain carbonic anhydrase II may
play a vital role in overall brain homeostasis maintenance with regards to cellular
pH, of which contributes to redox status as well as maintaining the common
theme of metabolic control, a well-known and common theme of dysfunction
throughout the progression of AD.

Cofilin-1 is a main actin regulatory protein which governs much of the dynamic
nature of the cytoskeleton. Actin dynamics is dramatically important in neuron
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and brain tissue health due to the directionality inherent in brain tissue cells.
Cofilin-1 dysregulation has been implicated in a number of neurodegenerative
disorders such as AD, Parkinson’s disease, and Huntington’s disease
(Schonhofen, de Medeiros et al. 2014, Bamburg and Bernstein 2016). Together
with actin depolymerizing factor (ADF), cofilin mediates the rapid assembly or
disassembly of actin which in turn allows for increased neuronal plasticity,
important for normal brain function and a detrimental loss in neurodegenerative
diseases like AD. Cofilin, however, is also a prime target for oxidation given
cofilin contains four free sulfhydryl groups that are easily oxidized in stressed
cellular environments which induces the formation of actin rod formation
(Pfannstiel, Cyrklaff et al. 2001). Damaged cofilin associates with bundled rods
and is hypothesized to be a detriment to amyloid-beta clearance to lysosomes in
the early stages of AD (Bamburg, Bernstein et al. 2010). Here, we show that
Cofilin-1 is reduced 0.51-fold (p=0.35* Ttest with high standard deviation) in the
Pin1 treated mice as opposed to that of the GFP treated mice. It is not clear if
this possible cofilin-1 reduction is due to association with rod-formation, similarly
to how Pin1 is lost in NFT, or if cofilin is being reduced in expression through
Pin1 overexpression, though future studies could elucidate this connection. While
decreased cofilin could potentially cause a loss of synaptic plasticity, it is also
possible that cofilin is being decreased in order to prevent rod formation, though
these are only speculations that need clarification. This cofilin interaction also
could be important due to the increased expression of ARP2/3 found within the
current study, since both are highly associated with synaptic plasticity and
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integrity with concerns to axonal growth cone control (Dumpich, Mannherz et al.
2015).

3.6 CONCLUSION
In conclusion, expression proteomics of Pin1 overexpression in AD model mice
resulted in a number of key proteins being identified as presenting with altered
levels which may aid in elucidating future areas for research into the role of Pin1
in AD progression. A common theme amongst the proteins identified was
structural integrity and plasticity, along with signaling events that appear to be
aimed at cell survival and proper endocytic trafficking and clearance. These
results shed new light on the role of Pin1 in a stressed cell, and future research
should be aimed at uncovering more of the downstream signaling effects of Pin1
upregulation.
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CHAPTER 4: INTRANASAL INSULIN ADMINISTRATION IN MOUSE MODELS
OF ALZHEIMER DISEASE AND INDUCED DIABETES: OXIDATIVE STRESS
AND EXPRESSION PROTEOMICS ANALYSIS
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4.1 OVERVIEW OF STUDY
Intranasal Insulin administration given to AD (APP/PS1) and induced diabetes
(dbdb) mice, and the cross between the two (dbdbxAPP/PS1), to determine the
effects of intranasal insulin on global oxidative stress measurements and
changes to the proteome with respect to treatment and genotype. Using
immunochemistry it was found that protein carbonyls were slightly, but
statistically significantly, decreased in the APP/PS1 and dbdbxAPP/PS1 mice by
approximately 9% in both groups. Expression proteomics was then employed to
determine the changes to the proteome between treatments and genotype and
uncovered a number of proteins important to different cellular processes such as
cellular signaling, structure, and metabolism.
4.2 INTRODUCTION:
The brain relies predominantly on its ability to quickly utilize glucose for the vast
majority of its energy needs. The brain is a highly metabolic organ, which, while
only comprising just about 2% of the average body weight of a human, utilizes
approximately 30% of the oxygen and 20% of the glucose intakes to meet the
brain’s energy requirements. The loss of normal glucose metabolism in AD
patients has been demonstrated using PET imaging as previously discussed (de
Leon, George et al. 1983, Jack, Petersen et al. 1999). The loss of glucose
utilization may be due to either the inability to uptake glucose from the circulatory
system or a loss of the ability to properly metabolically process the glucose within
the cells of the brain. Evidence has shown that both of these possibilities have
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merit (Frolich, Blum-Degen et al. 1998, Hoyer 2004, Butterfield and Lange 2009,
Butterfield, Galvan et al. 2010). More to the point, AD and insulin resistance
diseases share a number of commonalities such as increased oxidative stress,
cytokine activation, mitochondrial dysfunction, reduced insulin-stimulated growth
and survival, deficits in metabolic activity, and activation of the mammalian target
of rapamycin (mTOR) with consequent deleterious inhibition of autophagy (de la
Monte, Re et al. 2012, Li, Han et al. 2015, Tramutola, Triplett et al. 2015).

The peptide hormone insulin plays a major role in the energy homeostasis of the
body, regulating the uptake of circulating glucose for cellular utilization.
Specifically within the brain, insulin and the insulin-like growth factor 1 (IGF-1)
promote growth, survival, gene and protein expression, neurotransmitter
functionality, neuronal plasticity and synapse formation, and metabolism within
neurons and glia (de la Monte and Wands 2005, Joseph D'Ercole and Ye 2008).
Prolonged insulin resistance has been demonstrated to lead to increased plasma
lipids, hypertension, and a chronic loss of cellular energy (Dankner, Chetrit et al.
2009), which are likely to lead to the observed effects of the aforementioned PET
studies. In fact, while the genes for IGF-1/2 and insulin receptors are expressed
in both neurons and glia throughout the brain, both are reported to be particularly
dense in areas found to be affected by AD and other neurodegenerative
disorders indicating that these areas important for memory and cognition are
likely more reliant on glucose and insulin signaling (de la Monte and Wands
2005, de la Monte, Longato et al. 2009, de la Monte and Tong 2014).
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Poor glucose uptake by the brain likely results from systemic insulin resistance
resulting from prolonged states of hyperinsulinemia that accompanies
hyperglycemia, a state of high blood sugar that often times is associated with, or
a contributor to, obesity. Obesity not only leads to insulin resistance but also
significantly increases the risk for type-II diabetes mellitus (T2DM), metabolic
syndrome, and cognitive dysfunction (de la Monte and Wands 2008, Lyn-Cook,
Lawton et al. 2009, de la Monte and Tong 2014). In fact, obese patients
demonstrate impairments in executive function as well as a two-fold increased
risk of developing AD compared to a healthy individual (Gunstad, Paul et al.
2007, Yaffe 2007). The increased glucose intolerance and insulin resistance
associated with obesity increase the risk of MCI and AD, themselves (Gunstad,
Paul et al. 2007, Lokken, Boeka et al. 2009).

Insulin delivery via the intranasal route has been the focus of research due to the
indirect pathway to the brain through uptake into the olfactory nerve. The delivery
of drugs to the brain through the intranasal route is advantageous in comparison
to more traditional approaches such as intraperitoneal (IP) injection or oral
administration due to the ability to bypass the blood brain barrier (BBB), a major
obstacle in delivery therapeutics directly to the brain, using a non-invasive
procedure. Moreover, avoidance of insulin-dependent shock is avoided by bypassing the peripheral system for insulin delivery. Coupled with the finding that
nasal mucosa both express and deliver insulin to the brain with a normal
functioning neuroanatomical link between the olfactory and limbic system in
which both memory and cognitive function participate, intranasal insulin as a
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therapeutic for neurodegeneration was a logical target for investigation (Hanson
and Frey 2008). Indeed, intranasal insulin already has been shown to improve
cognitive function related to attention and verbal and hippocampal declarative
memory (Messier and Teutenberg 2005, Benedict, Hallschmid et al. 2007,
Benedict, Frey et al. 2011). Following INI, both memory and metabolic function in
MCI and AD subjects were improved; however those that were APO-ε4 positive
were shown to perform poorly on recall tasks compared to those that were APOε4 negative (Reger, Watson et al. 2006, Reger, Watson et al. 2008). From a
mechanistic point of view, insulin has been shown to increase the clearance of
amyloid from the brain, inhibit the activity of tau phosphorylating kinases, and
support neuronal cytoskeletal and cholinergic functions (de la Monte and Wands
2005, Reger, Watson et al. 2008, Schioth, Craft et al. 2012). However, more
research is needed in order to better understand the complex changes and
function of the proteome that occur in both Alzheimer and diabetic models with
the application of intranasal insulin. Here, we have used a combination of
Alzheimer and diabetic mouse models to determine the effects of intranasal
insulin administration on the formation of protein carbonyls, a common protein
oxidation marker, and the expression of downstream proteins in order to better
understand the effects of this novel mechanistic delivery of insulin.
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4.3 MATERIALS AND METHODS
4.3.1 MATERIALS
All chemicals used in these experiments were purchased from Sigma-Aldrich (St.
Louis, MO, USA) with some exceptions: Criterion precast polyacrylamide gels,
ReadyStripTM IPG strips (pH 3-10), Precision Plus ProteinTM All Blue Standards,
Sypro Ruby® Protein Stain, MOPS and TGS running buffers, mineral oil, 0.2 nm
nitrocellulose membrane, idodoacetamide (IA), dithiothreitol (DTT), biolytes, and
urea which were purchased from Bio-Rad (Hercules, CA, USA). Modified trypsin
solution was obtained from Promega (Madison, WI, USA) and the C18 ZipTips
were bought from Millipore (Billerica, MA, USA). Amersham ECL IgG horseradish
peroxidase-linked secondary antibodies and ECL-Plus Western blotting
chemiluminescent detection reagents were purchased from GE Healthcare
(Pittsburgh, PA, USA).
4.3.2 ANIMALS
The mouse models used in this experiment were genotyped and obtained from
the Michael P. Murphy laboratory at the University of Kentucky, Lexington KY.
For use in the experiments performed, four distinct mouse models were used:
C57BL/6 were used as the Wild Type (WT), APPΔNL/ΔNL/PS1P264L/P264L (APP/PS1)
were used as the AD model, db/db were used as the induced diabetic model, and
a cross between the db/db and the APP/PS1 (db/dbxAPP/PS1) were used as a
diabetic-Alzheimer model. The mice were housed in an AALAC-approved animal
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facility with a 12-hour light-dark cycle and fed the standard rodent chow ad
libitum. Prior to any experiment involving the use of animal models, University of
Kentucky (UK) IACUC approval was obtained and all work herein was performed
in accordance with all federal specifications.
All animals were subjected to IACUC approved wellness checks regularly and
throughout the duration of the study timeframe. Any animal deemed unfit to
continue the study due to perceived suffering was immediately euthanized.
All mice began treatment at 8 months of age and continued for two months until
the age of 10 months, where they were euthanized with slow introduction of
carbon dioxide followed by decapitation. Brain tissue was immediately harvested,
flash frozen in liquid nitrogen, and stored at 80 ͦC until use.
4.3.3 INTRANASAL INSULIN ADMINISTRATION
At 8 months of age, each mouse genotype wad divided into two groups (n=4) and
the mice were randomly assigned to either insulin or saline. Three times weekly,
the mice were administered via intra-nasal route 24 µL of either 0.86 units insulin
in 0.06% saline solution or 0.06% saline solution divided over four 6 µL aliquots
with 30 seconds in between administrations. If mice appeared to struggle with an
administration, they were allowed additional time to recuperate before the next
administration. If the mice exhaled the solution, or coughed it up after
administration, another administration was given after an appropriate amount of
time to allow the mouse to recuperate. The administrations continued for two
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months where the mice were then euthanized according to the procedures
previously mentioned.
4.3.4 SAMPLE PREPARATION
The brains from the m ice were thawed and individual homogenates were
prepared using a wheaton glass homogenizer (approximately 40-45 passes) with
ice-cold isolation buffer [0.32M sucrose, 2mM EDTA, 2mM EGTA, 20mM HEPES
buffer, 0.2µg/ml PMSF, 4µg/ml leupeptin, 4 µg/ml pepstatin, 5µg/ml aprotinin].
Homogenates were subsequently vortexed followed by sonication on ice for 10s
at 20% power, two times, allowing the sample to rest 20s on ice between
vortexings, with a Fisher 550 Sonic Dismembrator (Pittsburgh, PA, USA).
Concentration of the protein in the homogenates was determined by the Pierce
BCA method (Rockford, IL, USA).
4.3.5 PROTEIN CARBONYL SLOT BLOT
To determine the level of protein carbonyl to obtain an index of oxidative stress in
each sample, slot blot analysis was performed using the Bio-Dot SF 48-well (slot
format) apparatus obtained from Bio-Rad (Hercules, CA, USA). Prepared
samples (5 µL) were pipetted into a micro centrifuge tube followed by the addition
of 5 µL of 12% SDS solution. 2,4-dinitrophenylhydrazine (DNPH) in 2N HCL (10
µL of 10 mM) was added to each sample and incubated for a total of 20 min at
room temperature (RT) to allow derivativization. After 20 min incubation, the
samples were neutralized with 7.5 µL of 2M Tris in 30% glycerol and diluted to
100 µL with 1x PBS. Samples (250 ng) were loaded into each well onto a
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nitrocellulose membrane within the slot-blot apparatus and a vauum suction
applied. The membrane was removed and blocked with a blocking solution [3%
bovine serum albumin (BSA) in TBS + Tween (TBS+T)] for 1.5 hours.
Membranes were incubated with rabbit polyclonal anti-DNP antibody (1:100
dilution, OxyBlotTM Protein Oxidation Detection Kit) for 2 hours at RT. The blot
was then washed 3 times, 5 min each, with TBS+T and then incubated with
alkaline phosphatase-conjugated goat anti-rabbit secondary antibody (1:5000;
Sigma Aldrich, St. Louis, MO) for 1h at RT. Membranes were washed 3 times (5
min, 10 min, 10 min) followed by developing with 5-bromo-4-chloro-3-indolylphosphate/nitroblue tetrazolium (BCIP/NBT) color developing reagent for alkaline
phosphatase activity (Sigma Aldrich). Blots were subsequently dried and
scanned using a Bio-Rad ChemiDocTM XRS+ imaging system and quantified with
Image LabTM software (Bio-Rad, Hercules, CA, USA).

4.3.6 TWO-DIMENSIONAL POLYACRYLAMIDE GEL ELECTROPHORESIS
(2D-PAGE)
4.3.6.1 ISO-ELECTRIC FOCUSING
Brian tissue homogenates (200 µg) from the various mouse models were shaken
in 200 µl of rehydration buffer [8M urea, 2.0% (w/v) CHAPS, 2 M thiourea, 50 mM
dithiothreitol (DTT), 0.2% biolytes, 0.01% bromophenol blue] for 1.5 hr at RT
followed by sonication for 10 s at 20% power. The sonicated samples were
applied to 11 cm pH 3-10 ReadyStripTM IPG strips with a linear gradient. The IPG
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strips were actively rehydrated at 20°C for 18 h at 50 V utilizing a Bio-Rad
Protean IEF Cell (Hercules, CA, USA). After 60 min, 2 mL of mineral oil was
added to the strips to prevent dehydration. Subsequently, isoelectric focusing
was performed at a constant temperature of 20 °C starting at 300 V for 2 h, 500
V for 2 h, 1000 V for 2 h, 8000 V for 8 h, and finishing at 8000 V for 10H. The
IPG strips were then removed upon completion and stored at -80°C immediately
following removal and stored until future use.
4.3.6.2 SDS PAGE
IPG strips were thawed 10 min followed by 4 ml of a DTT-containing equilibration
buffer [50 mM Tris-HCl, pH 6.8, 6 M urea, 1% (w/v) SDS, 30% v/v glycerol, 0.5%
DTT] for 10 minutes in the absence of light. The strips were removed from
solution and placed in clean wells where 4 mL of an iodoacetamide-containing
buffer [50 mM Tris-HCl, pH 6.8, 6 M Urea, 1% (w/v) SDS, 30% v/v glycerol, 4.5%
iodoacetamide] was added, again in the absence of light. The IPG strips were
rinsed in a 1x dilution of TGS running buffer and placed into Criterion precast
linear gradient (8-16%) Tris-HCl polyacrylamide unstained gels. Precision Plus
ProteinTM All Blue molecular weight marker was added and agarose gel was
overlaid. Gels were run at a constant voltage of 200 V for approximately 60 min
using 1x Tris/Glycine/SDS running buffer.
4.3.6.3 IMAGE ANALYSIS
Spot intensities of the imaged unstained gels were quantified by densitometry
using PDQuest 2-D Analysis Software (Bio-Rad, Hercules, CA, USA). Individual
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gel spot intensities were normalized to the total density of the individual gel. Spot
densities from the eight experimental groups (WT(s), WT(i), APP/PS1(s),
APP/PS1(i), db/db(s), db/db(i), db/db x APP/PS1(s), and dbdb x APP/PS1(i))
were compared and the spots with a statistically significant difference based on
two-way ANOVA and Bonferonni multiple comparisons were considered for in-gel
trypsin digestion and identification of the protein of interest.
4.3.6.4 SYPRO RUBY STAINING
Following 2D-PAGE, and PDQuest analysis, sample gels (Criterion precast linear
gradient (9-16%) Tris-HCl polyacrylamide gels) were run rollowing the same
procedure but fixed in solution [7% (v/v) acetic acid, 10% (v/v) methanol] (50 mL)
for 45 min at RT on a gently orbiting platform. After fixing, the solution was
removed and 50 mL of Sypro Ruby® Protein Gel Stain was added to stain
proteins in the gel overnight (15 h) at RT with gentle orbiting. Gels were rinsed
and transferred to 50 mL of deionized water at RT until scanning. The Gels were
scanned utilizing a Bio-Rad ChemiDocTM XRS+ imaging system (Hercules, CA)
and subsequently stored in deionized water at 4°C until extraction of protein
spots.
4.3.6.5 IN-GEL TRYPSIN DIGESTION AND PEPTIDE EXTRACTION
Protein spots were identified as significant using PDQuest software and excised
from 2D-gels followed by transfer to Eppendorf micro-centrifuge tubes. 20 μL of
0.1 M ammonium bicarbonate (NH4HCO3) were added to the tubes and allowed
to incubate at RT for 15 min. Next, 30 μL of acetonitrile were added to each tube
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and again, incubated at RT for 15 min. The solvent was removed and gel plugs
allowed to dry at RT for 30 min. 30 μL of 20 mM DTT in 0.1 M ammonium
bicarbonate was added to the gel plugs and incubated for 45 min at 56°C.
Following the removal of the DTT/NH4HCO3 solution, 30 μL of 0.05 M
iodoacetamide (IA) in 0.1 M NH4HCO3 were added and incubated at RT for 15
min. The previous IA solution was removed and 150 μL of 0.05 M NH4HCO3
were added to incubate for 15 min at RT. 200 μL of acetonitrile (CAN) were then
added to the solutions and incubated for another 15 min. Gel plugs were dried for
30 min at RT before rehydrating with 10 μL of modified trypsin solution in 0.05 M
NH4HCO3. Gel plugs were incubated at 37 °C and shaken at 230 RPMs
overnight (15 hrs.). The resultant digest was transferred to Eppendorf tubes while
20 μL of a 5% CAN, 0.1% formic acid (FA) solution was added to the old tube
containing the gel plug and sonicated in a RT water-bath for 15 min. Following
water-bath sonication, 30 μL of a 95% CAN, 0.1% FA and 0.001 M NH4HCO3
solution were added and again water-bath sonicated for 15 min. The solution was
removed from the gel plug tube and combined with the supernatant digest
solution. Using a Speed-Vac, the digest solution samples were concentrated to a
volume of 10 μL. C18 ZipTips were used to remove remaining salts and
contaminants from the trypsin-digested peptide solution using the following
procedure. 10 μL of 100% CAN were aspirated into the ZipTip and expelled 5
times, followed by 10 μL of a 50% CAN solution containing 0.1% FA, which were
aspirated and ejected 5 times. The trypsin digested solution was drawn up and
pushed out of the column for a total of 10 times to allow for peptide adherence to
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the column. Contaminants were eliminated from the peptides through the ZipTip
by washing with 10 μL of a 5% CAN and 0.1% FA solution by aspirating and
expelling the eluent 5 times and the eluent stored at -80 degrees Celsius.
4.3.6.6 NANOLC-MS WITH DATA DEPENDENT SCAN
The samples described above were analyzed by a nanoAcquity (Waters, Milford,
MA)-LTQ Orbitrap XL (Thermo Scientific, San Jose, CA) system in a datadependent scan mode. An in-house packed capillary column (0.1 x 130 mm
column packed with 3.6 μm, 200 angstrom XB-C18) with a gradient with 0.1% FA
and CAN/0.1% FA at 200 nL/min were used for separation. The MS spectra were
acquired using an orbitrap at 30,000 resolution and MS/MS spectra of the six
most intense ions in the MS scan were attained by the orbitrap at 7,500
resolution. Subsequently, files from the samples were searched against the most
current version of the Swiss-Prot database by SEQUEST (Proteome Discoverer
v1.4, Thermo Scientific). A minimum of two high-confidence peptide matches are
required for protein identification (with a false discovery rate <1%). Proteins that
are matched with the same peptides are reported as one protein group.
Resultant MS/MS data were first verified by a comparison of the expected
molecular weight and isoelectric point of the identified protein to that of the
extracted plug from the 2-D gel.
4.3.7 STATISTICAL ANALYSIS
An ANOVA was performed followed by a Bonferroni correction for multiple
comparisons in order to determine the effects of intranasal insulin administration
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in Alzheimer and diabetic mouse models on the expression of proteins within the
tissue of the brain. An α<0.05 was selected as a measure of significance for the
ANOVA while a p<0.05 was selected as a measure of significance for the
multiple comparisons test. Fold-change values of any differentially expressed
proteins were determined by dividing the average spot intensity of the gels from
the Insulin groups by the average spot intensity of the gels of the saline group, or
to whichever group the comparison was being made for the individual protein
found to be differentially expressed. Proteins that were identified by the
SEQUEST search algorithm with p<0.01 were considered to be statistically
significant. To further validate MS/MS identification of significant differentially
expressed proteins, the position of protein spots on the 2D-gel images were
manually examined to confirm that they were located near the expected
molecular weight and isoelectric point values from the SwissProt database
information.

4.4 RESULTS
4.4.1 SLOT BLOT ANALYSIS
Protein carbonyl slot blots were performed on each group in order to determine
the effect of intranasal insulin administration on the formation of brain protein
carbonyls. In the wild-type group, there was no statistical difference between
insulin and saline administrations (Insulin: 100.06% of control; p=0.9). The
dbdbxWT/WT group showed a trend toward a decrease in protein carbonyls, yet
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was not statistically significant. The APP/PS1 group displayed a significant
decrease in protein carbonyls by 8.1% (p<0.05) with intranasal insulin
administration, while the dbdbxAPP/PS1 group showed a significant decrease in
protein carbonyls by 9.2% (p<0.002) following insulin administration.

Figure 4.4.1a: Representative dbdbxAPP/PS1 Insulin vs Saline Protein Carbonyl
(Trial 1) Slot Blot
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Figure4.4.1b: Representative dbdbxAPP/PS1 Insulin vs Saline Protein Carbonyl
(Trial 2) Slot Blot
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Figure4.4.1c: dbdbxAPP/PS1 Protein Carbonyl Trial 1 Slot Blot
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Figure 4.4.1d: dbdbxAPP/PS1 Protein Carbonyl Trial 2 Slot Blot
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Figure 4.4.1e: APP/PS1 Protein Carbonyl (Trial 1) Slot Blot
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Figure 4.4.1f: APP/PS1 Protein Carbonyl Trial 2 Slot Blot

4.4.2 EXPRESSION PROTEOMICS ANALYSIS
Proteomic analysis of the proteins of the insulin vs saline groups were conducted
using a 2D-PAGE approach with Sypro Ruby staining. Protein spot intensities
were compared between these four groups to determine differentially expressed
proteins. Figure shows representative examples of 2-D gel images of the isolated
proteins from the brain of the diabetic/Alzheimer mouse models given intranasal
insulin administration with the 9 labeled proteins that were found to be significant
differentially expressed. Figure shows representative examples of protein
carbonyl western-blot images of the isolated proteins from the brain of the
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diabetic/Alzheimer mouse models as a function of intranasal insulin
administration and with the 9 labeled proteins that were found to be significant
differentially expressed. In total, PDQuest analysis of all 8 groups of the 2-D
images found 9 protein spots suitable for extraction and whose expression or
oxidation was significantly altered in the brain. Protein spot extraction was
followed by in-gel trypsin digestion, peptide extraction, removal of metal ions with
buffers, and MS/MS analysis coupled to interrogation of protein databases to
determine the identity of the differentially expressed proteins.

Table 4.4.2 lists the 9 proteins that were found to be significant differentially
expressed in the brain of the Alzheimer and diabetic mouse models given
intranasal insulin or saline administration. These data provide added information
such as: the spot number as labeled by the PDQuest program, the SwissProt
accession number, percentage of the protein sequence covered by matching
peptides, the number peptide sequences identified by the tandem mass
spectrometry (MS/MS) analysis, the protein confidence score, the expected
molecular weight and isoelectric point of the identified protein, as well as the foldchange levels and p-values obtained from the PDQuest analysis. Fold-change
values were calculated by dividing the average spot intensity of the gel protein
spots of the dbdbXWT/WT, WTxAPP/PS1, and dbdbxAPP/PS1 by the average
spot intensity of the WT/WT/WT gel spots. To expound, a fold increase of 1.75 in
the dbdbxWT/WT group represents a 75% increase in protein expression of the
dbdbxWT/WT group compared to the group used as a control in the comparison.
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Moreover, a fold value less than 1, denotes a decrease in protein expression, for
example a fold of 0.5 represents a decreased protein expression of 50%.

As shown in Tables 4.4.2, all proteins (hereby referred to by shortened
accronyms of DbAPP (dbdbxAPP/PS1), Db (dbdb), APP (APP/PS1), and WT all
with either a suffix i or s as pertaining to their treatment group) were identified by
more than one peptide sequence. Further, proteins that were identified by
MS/MS analysis were preliminary validated by visually comparing the expected
molecular weight and isoelectric point provided by Sequest software to the
position of extracted protein spot on the gel. ATP synthase subunit d,
mitochondrial:2113 (↑0.146-fold, p=0.01, APPi v APPs), Synaptosomalassociated protein-25:2213 (↓0.0259-fold, p=0.0006, DbAPPi v Dbi; ↓0.0332-fold,
p=0.0007, DbAPPs v Dbi; ↓0.0318-fold, p=0.0007, APPi v Dbi; ↓0.0273-fold,
p=0.0007, APPs v Dbi; ↓0.0598-fold, 0.001, Wti v Dbi), Proteasome subunit alpha
type-5:2307 (↓0.0325-fold, p=0.01, APPi v APPs), Transitional endoplasmic
reticulum ATPase:2809 (↑5.7-fold, p=0.009, Dbi v Dbs; ↑3.55-fold, p=0.03, Dbi v
APPi; ↑5.16-fold, p=0.01, Dbi v Wti), Stathmin:3001 (↑4.7-fold, p=0.02, Dbi v Dbs;
↑5.12-fold, p=0.02, Dbi v APPi; ↑12.6-fold, p=0.002, Dbi v APPs), Growth factor
receptor-bound protein 2:4207 (↑2.77-fold, p=0.01, DbAPPi v
DbAPPs),Superoxide dismutase [Cu-Zn]:5002 (↓0.212-fold, p=0.02, DbAPPi v
Dbi), Voltage-dependent anion-selective channel protein 1:5105 (↓0.102-fold,
p=0.01, DbAPPi v DbAPPs), Hypoxanthine-guanine
phosphoribosyltransferase:6102 (↑4.72-fold, p=0.01, DbAPPi v DbAPPs; ↑5.6687

fold, p=0.008, DbAPPi v Dbi; ↑3.77-fold, p=0.02, DbAPPi v Dbs; ↑3.60-fold,
p=0.03, DbAPPi v Wt). Table 4.4.2 lists the 9 significant differentially expressed
proteins identified in the comparison of the Alzheimer and diabetic mouse models
and the comparisons therein.
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Table 4.4.2: Proteins with altered expression in brain of dbdbxAPP/PS1, dbdb,
APP/PS1, and Wildtype mice with insulin or saline administration
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Figure 4.4.2: Representative gels from the Insulin Study

4.5 DISCUSSION OF RESULTS
4.5.1 GLOBAL OXIDATIVE STRESS MEASUREMENTS
First it was important to verify whether or not intranasal insulin administration had
any significant impact on WT mice of any of the three oxidative stress measures
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investigated. As can be seen in Appendix A, no significant changes in PC, HNE,
and 3NT were observed in any measurement likely due to large internal standard
deviations between mice, which will be discussed below.

Protein carbonyls however were observed to be significantly reduced in the
APP/PS1 mouse model despite a very modest 9% decrease (Figure
4.4.1e;4.4.1f, p<0.05) . Both 3NT and HNE resulted in what appear to be a
decreasing trend of 30% (p=0.17) and roughly 16% (p=0.13) respectively
(Appendix A), but due to the variability between samples, the high standard
deviation in the saline groups in particular was too large to overcome for
significance despite acceptable sample variation, as seen in most cases.

The diabetic dbdb group too fell victim to high sample variation and standard
deviations despite, an acceptable confidence variable during blotting, resulting in
no significant change in any redox modification parameter tested. However, the
cross dbdbxAPP/PS1 model resulted in a very modest but statistically significant
reduction in protein carbonyls at nearly 10% (Figure 4.4.1c p<0.02; Figure 4.4.1d
p=0.068) while demonstrating no significant change in HNE or 3NT (Appendix A).
Because the mice used in this experiment appeared to have such variation and a
low sample size, those findings that were significant were repeated as can be
seen above for dbdbxAPP/PS1 and APP/PS1 protein carbonyls. This data
however, leaves much to be desired which could potentially be remedied by a
larger sample size and perhaps a shorter duration of experiment, as an
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unacceptable number of mice died during the two months of intranasal
administration. Due to these premature deaths, a number of mice were culled
from the study due to premature deaths either found in the cages or the result of
stroke or heart attack during the intranasal administration process. While this
data indicates that insulin may have been beneficial towards the reduction of
protein carbonyls in the AD model mice, any further findings would require
additional mice to further tease out additional effects and substantiate the
findings of this experiment.

4.5.2 EXPRESSION PROTEOMICS ANALYSIS
Insulin signaling is a complex intracellular signaling cascade that has many
downstream effects including energy regulation and transcription events (Thon,
Hosoi et al. 2016). Therefore, insulin interaction with brain tissue should have far
reaching downstream effects with regards to transcription and protein levels.
Nine proteins were identified as having statistically significant altered protein
levels in numerous comparisons in the utilization of two-way ANOVA method.
Because of the nature of an experiment such as this, where multiple
comparisons have to be made, many of the significant findings had to be
excluded because they resulted in non-sense comparisons (i.e. Protein A being
increased in the dbdb-insulin group over the APP/PS1-saline group). Through
focusing only on interesting and valid comparisons, we narrowed our initial
finding of approximately 76 statistically significant proteins down to nine through
ANOVA. These nine proteins are implicated in a wide range of cellular functions
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including energy production, synaptic transmission, oxidative stress mitigation
and proteasome function, cellular signaling, and structural integrity.

Energy and metabolic control are nearly synonymous with the word insulin in
most cases, as blood glucose levels is what insulin was first known to regulate.
ATP synthase, is the final enzymatic component to the long process of glycolytic
energy production beginning with glucose and ending with reducing factors such
as NADH being used to fuel a proton gradient that in turn mechanically rotates
ATP synthase and aids in the production of most of the cellular ATP used for
energy (Bernardi, Rasola et al. 2015). Here, we found that ATP synthase subunit
d, mitochondrial, was significantly decreased in APPi v APPs comparison (0.146fold, p=0.01). Energy dysfunction is a common theme in both AD and diabetes,
and ATP synthase is a common target of for differential expression (Tramutola,
Lanzillotta et al. 2016). Decreased levels of ATP synthase could be reflective of a
number of different causes, from decreased expression, to increased turnover or
protein degradation, particularly since components of ATP synthase were
identified by our laboratory using redox proteomics as being oxidatively modified
(Butterfield, Perluigi et al. 2012).

Synaptosomal-associated protein-25 (SNAP-25) is a t-snare protein and
component of the SNARE complex which is thought to allow membrane adhesion
and fusion of intracellular vesicles for exocytosis, as in neurotransmitter release
into the synapse. In the current study, SNAP25 levels were drastically increased
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in the dbdb-insulin group over nearly every other comparison (DbAPPi 0.0259fold, DbAPPs 0.0332-fold, APPi 0.318-fold, APPs 0.273-fold and WTi 0.0598-fold
in comparison to DBi) other than the dbdb-saline (still increased, but not
significant). This suggests that insulin in a diabetic mouse model not affected
with AD pathology saw an increase in SNAP25 which may result in better
synaptic transmission and communication. The Alzheimer models are likely not
rescued from damage occurring to SNAP25, which could constitute a loss of
protein level as opposed to solely an upregulation in the Dbi group as SNAP25,
which is consistent with literature suggesting that SNAP25 levels are decreased
and oxidatively modified in AD and other forms of dementia (Butterfield, Perluigi
et al. 2012, Bereczki, Francis et al. 2016).

The ability of the cell to effectively fold and process proteins during the
production and trafficking process is vitally important, as misfolded or damaged
proteins can cause aberrant functioning and even protein aggregation (Radwan,
Wood et al. 2017).The proteasome is a vital component in the cell for both
recycling cellular components, degrading damaged proteins, and degrading
proteins that have been tagged with ubiquitin in order to stop their function as in
the case of cell cycle proteins for example (Saeki 2017). In fact, E3-ubiqutin
ligases play large roles in insulin resistance and diabetes through the
degradation of important effector proteins and receptors (Yang, Xiang et al.
2016). The cells responsibility for producing correctly folded proteins and dealing
with misfolded proteins however is a complex process utilizing facets from
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multiple cellular organs, including the endoplasmic reticulum where many
proteins are first made and folded (Bhat, Chaudhary et al. 2016). The
Transitional endoplasmic reticulum ATPase is necessary for the energy
expenditure required by budding from the transitional endoplasmic reticulum
(tER), which is an ATP-dependent process. tER-ATPase is required for the
movement of unfolded or damaged proteins from the ER to the proteasome for
degradation, and damage to this vital component possibly results in accumulation
of damaged protein and a dysfunctional proteasome network (Zhang, Wang et al.
2015). tER-ATPase was found in the current study to be increased in the Dbi v
Dbs comparison (5.7-fold, p=0.009), Dbi v APPi (3.55-fold, p=0.03), and Dbi v
Wti (5.16-fold, p=0.01), and proteasome subunit alpha type-5 is significantly
decreased in the APPi v APPs (0.0325-fold, p=0.01) comparison. This drastic
increase in the Dbi v Dbs group for tER-ATPase appears to indicate that insulin
in the diabetic model has a much more pronounced effect whereas the
introduction of AD pathology appears to have no real effect upon insulin
administration. These results suggest that insulin signaling may play an important
role in attempting to maintain a functional and efficient proteasome network in a
diabetic model and not an AD model, as demonstrated by the diabetic model.
However, due to the fact that that the DbAPP model does not show this change,
reflects that the AD pathology may negate any positive change due to insulin in
the diabetic part of the model. It is widely known that proteasome is deficient in
AD resulting in abandoned endosomes propagating amyloid-beta production,
though it appears that insulin has no mitigating effect unless diabetic pathology is
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present.

Stathmin is a microtubule-destabilizing phosphoprotein. Stathmin functions by
depolymerizing microtubules through the sequestering of free tubulin dimers,
while also engaging in inducing microtubule-catastrophe (Gupta, Li et al. 2013).
Microtubule dynamics and instability is paramount to a normally functioning cell,
especially one that relies upon polarity and large scale endocytic trafficking such
as neurons and other brain cells. Stathmin helps govern microtubule growth and
shrinkage through the association with free tubulin, providing an indirect
mechanism and means for endocytic transportation, mitochondrial recycling, and
synaptic vesicle translocation (Gupta, Li et al. 2013). In the current study,
Stathmin was found to be significantly increased in the Dbi v Dbs comparison
(4.73-fold, p=0.01), Dbi v APPi (5.12-fold, p=0.02), and Dbi v APPs (12.6-fold,
p=0.002). Our data suggest that the Alzheimer model with insulin administration
does not receive the mitigating benefit to stathmin level that the diabetic group
alone does, which is consistent with literature suggesting that stathmin is
significantly decreased in AD brain (Jin, Masliah et al. 1996, Cheon, Fountoulakis
et al. 2001). Moreover, there was no statistical difference between the DbAPPi v
DbAPPs group which leads one to infer that the Alzheimer part of the model is
responsible for the lack in Stathmin recovery. Cellular transport of vesicles and
organelles is of the utmost importance for the maintenance of healthy neurons.
AD, among others, is fraught with microtubule dysregulation as evidenced by
NFT formation with protein tau, and evidence of vesicles that have failed to
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merge with lysosomes found in early AD (Arendt, Stieler et al. 2016).

Growth factor receptor-bound protein 2 (Grb2) interacts with nearly all receptor
tyrosine kinases by way of their intracellular tail and SH2 domain interaction.
Grb2 recruits effector proteins to localize together in order to engage in
downstream signal transduction. More information regarding the cellular actions
of Grb2 can be found in Chapter 3 discussion (Jang, Zhang et al. 2009, Belov
and Mohammadi 2012). Grb2 has more recently been found to also be involved
in cellular transport, utilizing the ability to bind proteins and recruit them to
membrane systems such as autophagasomes (Roy, Chakrabarti et al. 2014). As
discussed previously, Grb2 has been implicated in the binding of AICD of APP
and co-localization in the autophagasome suggesting a possible APP clearance
mechanism for Grb2 (Roy, Chakrabarti et al. 2014). This finding also is important
when considering the induced diabetic model, DbAPP, as autophagy
dysregulation has been evident for some time in metabolic diseases such as
diabetes mellitus type-2 (Demirtas, Guclu et al. 2016). Whether this upregulation
is due in part to the AD or metabolic component of this genotype has yet to be
concluded, though it can be posited that this upregulation of Grb2 may well be an
attempt to not only put a tighter grip on signaling ability, but also possibly
increase the cells’ ability to utilize autophagy for either energy efficiency, waste
control, or both. Grb2, in the current study, was found to be increased in the
DbAPPi v DbAPPs (2.77-fold, p=0.01). Since Grb2 is in large part responsible for
the recruitment of effector proteins to TRKs like insulin receptors, it is to be
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expected that a diabetic model such as the DbAPP model would present with an
increase in Grb2 levels corresponding to increased signaling activity due to
downstream insulin signaling.

Superoxide dismutase [Cu/Zn] is located within the cytosol, as opposed to
manganese SOD within the mitochondria, yet they share the same physiological
role of scavenging and reducing superoxide to hydrogen peroxide, a less reactive
form of ROS, though longer lived and still reactive (Abreu and Cabelli 2010).
However, though the canonical role of SOD may be ROS scavenging, new
insights into SOD show that it may be a pleiotropic enzyme involved in cell
survival signaling pathways by way of ERK1/2 and AKT activation, possibly
through or resulting in intracellular calcium release. SOD was found to be
significantly decreased in the DbAPPi v Dbi comparison (0.212-fold, p=0.02).
From this comparison, it appears as if the Alzheimer pathology introduced to the
diabetic model has a negative effect on SOD levels. Higher SOD levels in
diabetic models with insulin administration may indicate a pro-survival pathway
activation, though elucidation as to the pathway activated remains to be clarified.

The mitochondrial permeability transition pore (MPTP) is a structure formed on
the surface of mitochondria that is vastly associated with cytochrome c release
and apoptosis (Kinnally, Peixoto et al. 2011). Voltage-dependent anion selective
channel protein 1 (VDAC1), in the open state, allows for the translocation of ATP,
ADP and inorganic phosphate and calcium, among other metabolites such as
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pyruvate in and out of the mitochondria. In the closed state, only calcium is
allowed to be released into the cytosol and no larger molecules are allowed in,
which helps regulate calcium signaling and energy production (McCommis and
Baines 2012). VDAC1, being an important constituent of the MPTP, also helps
regulate apoptosis when the cell experiences stressors such as high levels of
oxidative stress. When activated, the MPTP opens releasing pro-apoptotic
proteins which includes cytochrome-c whereby programmed cell death occurs. A
recent study utilizing the overexpression of MicroRNA-7 (miR-7), a non-coding
RNA that has been implicated in a protective role in cellular Parkinson disease
models, showed inhibition of mitochondrial fragmentation, depolarization,
oxidative stress generation, and cytochrome-c release in SH-SY5Y cell lines and
confirmed in mouse primary neurons (Chaudhuri, Choi et al. 2016). Moreover, it
was shown that miR-7 down-regulated the expression of VDAC1 through
targeting VDAC1 mRNA. Subsequent down-regulation of VDAC1 resulted in
decreased cellular oxidative stress and protection against 1-methyl-4phenylpyridinium (MPP(+)), a molecule that induces calcium induced cytotoxicity.
The overregulation of VDAC1 overcame the protective effects of miR-7 against
MPP(+) (Chaudhuri, Choi et al. 2016). In the present dissertation study, VDAC1
was found to be significantly reduced in the DbAPPi v DbAPPs comparison
(0.102-fold, p=0.01). This finding suggests that intra-nasal insulin administration
may have a protective effect in the highly stressed DbAPP genotype through the
downregulation of VDAC1. While the activity of miR-7 in the examined mouse
genotypes are beyond the scope of this dissertation study, it has also been found
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that miR-7 targets the insulin-like growth factor 1 receptor, inhibiting glucose
metabolism and cellular growth likely through the regulation of the IGF-1R/AKT
signaling pathway (Wang, Sun et al. 2014). This connection may indicate that
IGF-1R/AKT activity and levels may lead to decreased VDAC1 levels through
insulin receptor cross-talk, inducing a protective state in the highly stressed
DbAPP model mouse, though the connection between IGF-1R, miR-7, and
VDAC1 in Alzheimer and diabetic states would need further investigation.

Hypoxathine-guanine phosphoribosyltransferase (HPRT), catalyzes production of
inosine monophosphate and guanine from hypoxanthine and guanosine
monophosphate, respectively, thus HPRT is intricately involved in purine
synthesis by way of the purine salvage pathways (Gherardi and Sarciron 2007).
Like most salvage pathways, the end result is a recycling of material for
repurposing which is an important biochemical function that saves the cell energy
costs associated with the expenditure required for de novo synthesis, but more
important in tissue types that lack the ability to synthesize the materials at all. In
the current study, HPRT was found to be significantly increased in the DbAPPi v
DbAPPs (4.72-fold, p=0.01), DbAPPi v Dbi (5.66-fold, p=0.008), DbAPPi v Dbs
(3.77-fold, p=0.02), and DbAPPi v Wt (3.60-fold, p=0.03). As of this writing, it is
not clear the relationship between HPRT and AD or diabetes with insulin
administration, though it could be presumed that insulin administration and the
subsequent increase in protein levels observed in this dissertation study reflect
an attempt by the cell to increase purine turnover much like a proteasome
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recycles damaged or ubiquitin-tagged proteins. It is possible that this increase in
purine salvage represents the attempt to mitigate the oxidatively damaged
nucleotides that have been shown to occur in AD models and brain (Drake,
Petroze et al. 2004, Lovell, Soman et al. 2011). However, as nucleotide oxidative
modification was beyond the scope of the proteomics experiments within this
dissertation study, follow-up studies quantifying nucleotide oxidative
modifications could help clarify this finding.

4.6 Conclusion:
In conclusion, this dissertation study, while marred by low sample size and high
internal standard deviation, did uncover a few interesting findings. It was found
that protein carbonyls were modestly, but significantly, decreased in the induceddiabetic/Alzheimer mouse genotype by roughly 10%, and in the APP/PS1 model
by 9%. What is more, is that expression proteomics uncovered a number of
proteins experiencing significant changes in expression with the introduction of
intra-nasal insulin administration as compared to the saline administered mice.
These proteins span a wide range of cellular systems including the proteasomal
and apoptotic pathways, energy production, and oxidative stress management. In
the future, if these findings are to be elaborated upon further, reducing the age at
which the administration occurs and the duration of the administration would
likely result in higher animal retention while simultaneously yielding interesting
results. Moreover, using ANOVA analysis resulted in quite confusing and often
confounding comparisons which may have been better suited simply comparing
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the insulin and saline administrations for each genotype separately with a 2-tailed
Ttest, having the additional effect of retaining more protein comparisons than this
dissertation study yielded.
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CHAPTER 5: COMPARATIVE PROTEOMIC ANALYSES OF THE PARIETAL
LOBE FROM RHESUS MONKEYS FED A HIGH FAT/SUGAR DIET WITH AND
WITHOUT RESVERATROL SUPPLEENTATION, RELATIVE TO A HEALTHY
DIET: INSIGHTS INTO THE ROLES OF UNHEALTHY DIETS AND
RESVERATROL ON FUNCTION

103

5.1 OVERVIEW OF STUDY
A diet consisting of a high intake of saturated fat and refined sugars is
characteristic of a Western-diet and has been shown to have a substantial
negative effect on human health. Expression proteomics were used to investigate
changes to the parietal lobe proteome of rhesus monkeys consuming either a
high fat and sugar (HFS) diet, a HFS diet supplemented with resveratrol
(HFS+RSV), or a healthy control diet for 2 years. Here we discuss the
modifications in the levels of 12 specific proteins involved in various cellular
systems including metabolism, neurotransmission, structural integrity, and
general cellular signaling following a nutritional intervention. Our results
contribute to a better understanding of the mechanisms by which resveratrol
functions through the up- or down-regulation of proteins in different cellular subsystems to affect the overall health of the brain.

5.2 INTRODUCITON
The Western diet consists of a high amount of saturated fat and refined sugar
(HFS) content commonly used in food preparation. Long term consumption of
HFS has been linked to a number of physiological conditions such as obesity,
insulin resistance and type-2 diabetes mellitus, cardiac disease, ischemia,
cancer, and cognitive dysfunction (Myles 2014). The projected costs of obesityrelated diseases are measured not only in monetary terms, but also in life-years
used to treat the disease and life-years lost to early death associated with obesity
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and unhealthy diets in general.

Resveratrol (RSV) is a polyphenol found primarily in red grapes, blueberries,
cranberries, nuts such as peanuts and pistachios, as well as in cocoa. RSV has
garnered widespread acclaim due to the many studies linking it to beneficial
effects such as neuroprotection, anti-inflammation, regulation of metabolic
pathways, improved glucose tolerance, and as an antioxidant (Carrizzo, Forte et
al. 2013, Bastianetto, Menard et al. 2014, Szkudelski and Szkudelska 2014,
Poulsen, Fjeldborg et al. 2015). The mode of action for RSV appears to be its
indirect activation of the NAD+-dependent deacetylase, sirtuin-1 (SIRT1),
possibly through the inhibition of cyclic AMP (cAMP)-degrading
phosphodiesterase, that leads to the deacetylation of the p65 subunit of NF-κB
(Howitz, Bitterman et al. 2003, Blander and Guarente 2004, Dai, Kustigian et al.
2010, Park, Ahmad et al. 2012).

The parietal lobe of the brain is primarily responsible for the integration of
sensory information, both tactile and perceived, as well as spatial recognition and
processing of both language and memory. Impairments to the parietal lobe are
seen in a number of neurodegerative diseases such as Alzheimer disease (AD),
Parkinson disease, and amyotrophic lateral sclerosis (Cosottini, Pesaresi et al.
2012, Teixeira, Machado et al. 2014, Brickman, Zahodne et al. 2015). AD in
particular, along with its earlier stage, amnestic-mild cognitive impairment
(aMCI), have been linked to proteome dysfunction in most regions of the brain,
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including parietal lobule, indicating that a healthy and functioning proteome is
necessary for normal brain function (Di Domenico, Owen et al. 2010, Aluise,
Robinson et al. 2011). Although there has been considerable research on the
effects of RSV in a number of scenarios and models, a proteomic analysis of the
primate brain has yet to be conducted. With 95% genetic homology, rhesus
monkeys are an ideal translational model toward understanding the effects of a
Westernized diet and the influence of RSV supplementation in a primate brain,
modeling humans. Through the use of discovery-based proteomics methodology,
the current study led to the identification of parietal proteins important in energy
production, cellular signaling, and neurotransmission within the proteome of
rhesus monkey parietal lobe which might play a role in neurodegenerative
disease or dysfunction associated with an unhealthy diet.

5.3 MATERIALS AND METHODS
5.3.1 MATERIALS
The chemicals used in these experiments were purchased from Sigma-Aldrich
(St. Louis, MO, USA) with the following exceptions: Criterion precast
polyacrylamide gels, ReadyStrip™ IPG strips (pH 3-10), Precision Plus Protein™
All Blue Standards, Sypro Ruby® Protein Stain, MOPS and TGS running buffers,
0.2 nm nitrocellulose membrane, mineral oil, dithiothreitol, iodoacetamide,
biolytes, and urea were purchased from Bio-Rad (Hercules, CA, USA). Modified
trypsin solution was obtained from Promega (Madison, WI, USA) and C18 ZipTips
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were acquired from Millipore (Billerica, MA, USA). Anti-alpha-internexin and antichloride intracellular channel protein antibodies were procured from Santa Cruz
(Dallas, TX, USA). Amersham ECL IgG horseradish peroxidase-linked secondary
antibodies, ECL-Plus Western blotting chemiluminescent detection reagents as
well as Re-Blot Plus Strong stripping solutions were purchased from GE
Healthcare (Pittsburgh, PA, USA).
5.3.2 Animals
Twenty-three adult (7-13 years old) male rhesus monkeys (Macaca mulatta)
were housed at the NIH Animal Center, Poolesville, MD, a center fully accredited
by the American Association for Accreditation of Laboratory Animal Care. All
procedures were approved by the Animal Care and Use Committee of the NIA
Intramural Program.
5.3.3 EXPERIMENTAL DIET
Monkeys were randomized into one of three groups: a healthy standard diet
(Cont, n= 3) or a high fat/high sugar diet in combination with either placebo (HFS,
n=10) or resveratrol (HFS+RSV, n=10). The Cont diet was a standard purified
chow consisting of 13% of kcal in fat and less than 5% sucrose by weight (Purina
Mills, St. Louis, MO). The HFS diet was a specially formulated purified ingredient
diet with 42% of kcal in fat and approximately 27% sucrose by weight (Harlan,
Teklad, Indianapolis, IN). The monkeys were gradually switched to the HFS diet
over a 3-week period. Monkeys received 2 meals per day at estimated ad libitum
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levels throughout the study and water was always available. The average food
consumption (kcals/day) for weekly periods was the same for all groups.
The RSV dose was derived from the protective dose reported in mice (22 mg/kg)
(Baur, Pearson et al. 2006) and adjusted by allometric scaling to an average
monkey body weight of 12.1 kg. RSV was supplied by DSM Nutritional Products,
Parsippany, NJ. HFS+RSV monkeys received 40 mg RSV twice a day for the first
year which was increased to 240 mg twice a day during the second year in order
to raise plasma RSV levels. The HFS and Cont monkeys received a placebo
treat (Bio-Serv, Frenchtown, NJ). Additional experimental details have been
described previously (Fiori, Shin et al. 2013, Jimenez-Gomez, Mattison et al.
2013, Mattison, Wang et al. 2014).
5.3.4 SACRIFICE AND TISSUE HARVEST
Anesthesia was induced with Ketamine (7-10 mg/kg, IM) and, following blood
collection, the monkeys were deeply anesthetized with a lethal dose of sodium
pentobarbital (50 mg/kg, IP). Once maximally sedated, the monkeys were perfused
with cold lactated Ringer’s solution. Tissues were harvested immediately, flash
frozen in liquid nitrogen, and stored at -80˚C until use.
5.3.5 SAMPLE PREPARATION
The parietal lobules from the brains of rhesus monkeys were thawed at 4°C and
individual homogenates were prepared with a Wheaton glass homogenizer
(approximately 40 passes) with ice-cold isolation buffer [0.32M sucrose, 2mM
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EDTA, 2mM EGTA, 20mM HEPES, 0.2µg/ml PMSF, 4µg/ml leupeptin, 4 µg/ml
pepstatin, 5 µg/ml aprotinin]. Homogenates were thoroughly vortexed and
subsequently sonicated on ice for 10 s at 20% power, a total of two times,
allowing the sample to rest 20 s on ice between vortexings, with a Fisher 550
Sonic Dismembrator (Pittsburgh, PA, USA). Concentration of the total protein in
the homogenates was determined by the Pierce BCA method (Rockford, IL,
USA).

5.3.6 TWO DIMENSIONAL POLYACRYLAMIDE GEL ELECTROPHORESIS
(2D-PAGE)
5.3.6.1 ISOELECTRIC FOCUSING
Parietal lobe tissue homogenates (200 µg) were shaken in 200 µl of rehydration
buffer [8 M urea, 2.0% (w/v) CHAPS, 2 M thiourea, 50 mM DTT, 0.2% biolytes,
0.01% bromophenol blue] for 1.5 hr at RT and then sonicated for 10 s at 20%
power. Samples were applied to 11 cm pH 3-10 ReadyStrip™ IPG strips with a
linear gradient. IPG strips were actively rehydrated at 20 °C for 18 h at 50 V
using a Bio-Rad Protean IEF Cell (Hercules, CA, USA). After the first 60 min, 2
mL of mineral oil was added to the strips. Next, isoelectric focusing was carried
out at a constant temperature of 20 °C beginning at 300 V for 2 h, 500 V for 2 h,
1000 V for 2 h, 8000 V for 8 h, and ending at 8000 V for 10 h. The IPG strips
were immediately stored at -80 °C until use.
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5.1.5.2 SDS PAGE. IPG strips were thawed for 10 min and then 4 ml of a DTTcontaining equilibration buffer [50 mM Tris–HCl, pH 6.8, 6 M urea, 1% (w/v) SDS,
30% v/v glycerol, 0.5% DTT] was added for 10 min in the dark. This solution was
removed and 4 ml of an iodoacetamide-containing buffer [50 mM Tris–HCl, pH
6.8, 6 M urea, 1% (w/v) SDS, 30% v/v glycerol, 4.5% iodoacetemide] for 10 min
in the dark. IPG strips were then rinsed in a 1X dilution of TGS running buffer and
placed into Criterion precast linear gradient (8–16%) Tris–HCl polyacrylamide
gels. Precision Plus Protein™ All Blue molecular weight marker was added and
agarose gel was overlaid. Gels were run at a constant voltage of 200 V for
approximately 65 min until completion using 1X Tris/Glycine/SDS running buffer.
5.3.6.2 SYPRO RUBY STAINING
Following 2D-PAGE, gels were fixed in solution [7% (v/v) acetic acid, 10% (v/v)
methanol] (50 ml) for 45 min at RT on a gently orbiting platform. Next, the fixing
solution was removed and 50 ml of Sypro Ruby® Protein Gel Stain was added
and stained proteins in the gel overnight (15 h) at RT with gentle orbiting. Gels
were rinsed and transferred to 50 ml of deionized water at RT until scanning.
Gels were scanned using a Bio-Rad ChemiDocTM XRS+ imaging system
(Hercules, CA) and stored in deionized water at 4 °C until extraction of protein
spots.
5.3.6.3 IMAGE ANALYSIS
Spot intensities of the imaged SYPRO Ruby®-stained 2D gels were quantified by
densitometry using PDQuest 2-D Analysis Software (Bio-Rad, Hercules, CA,
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USA). Individual gel spot intensities were normalized to the total density of the
respective gel. Spot densities from the three sample groups (Cont, HFS,
HFS+RSV) were compared and spots with a statistically significant difference
based on a Student’s two-tailed t-test (p<0.05) were considered for in-gel trypsin
digestion and the subsequent identification of the protein.
5.3.6.4 IN-GEL TRYPSIN DIGESTION AND PEPTIDE EXTRACTION
Statistically significant protein spots were excised from 2D-gels and transferred
to Eppendorf microcentrifuge tubes. Next, 20 µL of 0.1 M ammonium bicarbonate
(NH4HCO3) was added to each tube and incubated at RT for 15 min, followed by
an addition of 30 µL of acetonitrile at RT for 15 min. The solvent was removed
and gel plugs dried at RT for approximately 30 min. Then, 30 µl of 20 mM DTT in
0.1 M NH4HCO3 was added to the gel plugs and incubated for 45 min at 56°C.
After removal of the DTT/NH4HCO3 solution, 30 µl of 0.05 M iodoacetamide (IA)
in 0.1 M NH4HCO3 was added and gel plugs incubated at RT for 15 min. The IA
solution was then removed and 150 µl of 0.05 M NH4HCO3 was added to
incubate for 15 min at RT. Next, 200 µl of acetonitrile (ACN) was added to this
solution and incubated for an additional 15 min. Gel plugs were dried for 30 min
at RT before rehydrating with 10 µl of modified trypsin solution in 0.05 M
NH4HCO3. Plugs were incubated at 37 °C and shaken at 230 RPMs for 15 hrs.
The digest solution was transferred into a new Eppendorf tube and then 20 µl of
a 5% ACN, 0.1% formic acid (FA) solution was added to the old tube containing
the gel plug and sonicated in a bath for 15 min. To this, 30 µl of a 95% ACN,
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0.1% FA and 0.001 M NH4CO3 solution was added and sonicated for 15 min. The
solution was removed from the gel plug tube and combined with the supernatant
digest solution. Using a Speedy Vac, the samples were subsequently
concentrated to a volume of approximately 10 µl. Salts and contaminants were
removed from the trypsin-digested peptide solution with C18 ZipTips. 10 µl of
100% ACN was aspirated into the tip and expelled a total of 5 times. Next, 10 µl
of a 50% ACN solution containing 0.1% FA was aspirated and ejected a total of 5
times. The trypsin digested solution was then slowly drawn up and pushed gently
out of the column a total of 10 times for peptide adherence. The contaminants
were eliminated from the peptides in the ZipTip by washing with 10 µl of a 5%
ACN and 0.1% FA solution a total of 3 times. Peptides were extracted from the
column with 10 µl of a 50% ACN and 0.1% FA solution by slowly drawing up and
expelling the eluent a total of 5 times. Samples were stored at -80˚C until MS
analysis.
5.3.6.5 NANOLC-MS WITH DATA DEPENDENT SCAN
The de-salinated samples were reconstituted in 10 µL 5% ACN/0.1% FA and
analyzed by a nanoAcquity (Waters, Milford, MA)-LTQ Orbitrap XL (Thermo
Scientific, San Jose, CA) system in data dependent scan mode. An in-house
packed capillary column (0.1 x 130 mm column packed with 3.6 µm, 200Å XBC18) and a gradient with 0.1% FA and ACN/0.1% FA at 200 nL/min were used
for separation. The MS spectra were acquired by the orbitrap at 30,000
resolution and MS/MS spectra of the six most intense ions in MS scan were
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obtained by the orbitrap at 7,500 resolution. Data files from each sample were
searched against the most current version of the Swiss-Prot database by
SEQUEST (Proteome Discoverer v1.4, Thermo Scientific). A minimum of two
high-confidence peptide matches were required for protein identification (false
discovery rate <1%). Proteins matched with the same peptides are reported as
one protein group. Resultant MS/MS data were initially verified by comparison of
the expected molecular weight and isoelectric point of the identified protein to
that of the extracted plug from the 2-D gel.
5.3.7 ONE DIMENSIONAL POLYACRYLAMIDE GEL ELECTROPHORESIS (1DPAGE)
Parietal lobule homogenates (50 µg) were suspended in 4X sample loading
buffer [0.5 M Tris, pH 6.8, 40% glycerol, 8% SDS, 20% β-mercaptoethanol,
0.01% Bromophenol Blue] diluted to 1X with distilled water. Samples were then
heated at 95 °C for 5 min, cooled on ice and loaded into a CriterionTM precast (412%) Bis-Tris polyacrylamide 12 well gel with Precision Plus Protein™ All Blue
Standards. Gels were run at RT in a Criterion Cell™ vertical electrophoresis
buffer tank (Bio-Rad, Hercules, CA, USA) containing a 1X dilution of XT MOPS
running buffer at 80 V for 15 min. Voltage was then increased to 120 V for the
duration of the electrophoretic run (approximately 100 min).
5.3.7.1 1D-WESTERN BLOTTING
Proteins in the gel were transferred to a nitrocellulose membrane (0.2 nm) using
a Trans-Blot TurboTM Blotting System (Bio-Rad, Hercules, CA, USA). After the
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transfer, membranes were placed in a blocking solution of 3% bovine serum
albumin (BSA) in Wash Blot [150 mM NaCl, 3 mM NaH2PO4, 17 mM NaHPO4
and 0.04% (v/v) Tween 20] at RT for 1.5 h. Alpha-internexin and anti-chloride
intracellular channel proteins were detected with polyclonal primary antibodies
raised in rabbits (1:8000 dilution in blocking solution.) Blots were incubated at RT
with gentle rocking for 2 h. Next, the membranes were rinsed three times in
Wash Blot (5 min, 5 min, 10 min), followed by a 1 h incubation with a rabbit
horseradish peroxidase (1:3000) secondary antibody at RT with gentle rocking.
Blots were rinsed three times (5, 10 and 10 min) in Wash Blot and developed
chemiluminescently using ClarityTM Western ECL Substrate. After developing for
5 min at RT in the dark, blots were scanned using a Bio-Rad ChemiDocTM XRS+
imaging system and quantified using Image LabTM software (Bio-Rad, Hercules,
CA, USA). The membranes were then rinsed with Wash Blot for 5 min, two times,
and then stripped with Re-Blot Plus Strong solution for exactly 10 min at RT,
followed by three 5 min rinses with Wash Blot. The membranes were then
blocked once again in 3% BSA for 1.5 h. Next, anti-tubulin antibodies raised in
mice (1:20000) were added to the Wash Blot solution for 2 h of gentle rocking at
RT. Membranes were then washed, incubated with a secondary HRP-conjugated
antibody, washed, developed chemiluminescently and scanned as described
above.
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5.3.8 STATISTICAL ANALYSIS
An ANOVA was performed followed by a Bonferroni correction for multiple
comparisons in order to determine the effects of HFS and HFS+RSV diets on the
expression of proteins within the tissue of the parietal lobule. An α<0.05 was
selected as a measure of significance for the ANOVA while a p<0.05 was
selected as a measure of significance for the multiple comparisons test. Foldchange values of differentially expressed proteins were determined by dividing
the average spot intensity of the gels from the HFS or HFS+RSV diet groups by
the average spot intensity of the gels of the Cont diet group. For the fold-change
comparisons between the HFS and the HFS+R, the average spot intensities of
the gels from the HFS+RSV were divided by those of the gels from the HFS diet.
Proteins that were identified by the SEQUEST search algorithm with p<0.01 were
considered to be statistically significant. To further validate MS/MS identification
of significant differentially expressed proteins, the position of protein spots on the
2D-gel images were manually examined to confirm that they were located near
the expected molecular weight and isoelectric point values from the SwissProt
database information.
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5.4 RESULTS
5.4.1 EXPRESSION PROTEOMICS ANALYSIS
Proteomic identifications of proteins from rhesus monkey parietal lobules
following two years of a diet intervention were conducted using a 2D-PAGE
approach with Sypro Ruby staining. Protein spot intensities were compared
between these three groups to determine differentially expressed proteins. Figure
5.4.1a shows representative examples of 2-D gel images of the isolated proteins
for the Cont and HFS comparison with the five differentially expressed proteins
identified and listed in Table 5.4.1a. Gel images for the Cont and HFS+RSV
comparison are shown in Figure 5.4.1b. Five proteins were identified and listed in
Table 5.4.1b. Figure 5.4.1c illustrates the four differentially expressed proteins
between HFS and HFS+RSV diet groups which are listed in Table 5.4.1c.
PDQuest analysis of 2-D images for all three groups identified protein spots
suitable for extraction and whose expression was significantly altered in the
parietal lobules, and five of the proteins were significant in multiple comparisons.
Protein spot extraction was followed by in-gel trypsin digestion, peptide
extraction, removal of metal ions with buffers, and MS/MS analysis coupled to
interrogation of protein databases. All proteins were identified by more than one
peptide sequence.
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Table 5.4.1a: Proteins with altered expression in parietal lobe of Rhesus
monkeys in the Control vs HFS comparison

Figure 5.4.1a: Representative excision gels Rhesus Monkey (Cont vs HFS)
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Table 5.4.1b: Proteins with altered expression in parietal lobe of Rhesus
monkeys in the Control vs HFS+R comparison

Figure 5.4.1b: Representative excision gels Rhesus Monkey (Cont vs HFS+R)

118

Table 5.4.1c: Proteins with altered expression in parietal lobe of Rhesus
monkeys in the HFS vs HFS+R comparison

Figure 5.4.1c: Representative excision gels Rhesus Monkey (HFS vs HFS+R)
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Fold-change values were calculated by dividing the average spot intensity of the
gel protein spots of the HFS or HSF+RSV diet group by the average spot
intensity of the Cont diet gel spots, or by dividing the average spot intensity of the
gel protein spots of the HFS+RSV by the average spot intensity of the gel protein
spots of the HFS diet. To expound, a fold increase of 1.75 in the HFS+RSV
group represents a 75% increase in protein level of the HFS+RSV group
compared to the group used as a Cont in the comparison. Moreover, a fold value
less than 1, denotes a decrease in protein level; for example, a fold-change of
0.25 represents a decreased protein level of 75%.
5.4.2 WESTERN-BLOT VALIDATION EXPERIMENTS
Western blot experiments were conducted on a selected protein to validate the
changes in protein levels as determined by the PDQuest analysis of the 2-D gels.
Figure 4 is a Western blot image of the three groups after probing with chloride
intracellular channel protein and tubulin antibodies. Analysis of this blot showed a
65.6% decrease in levels of chloride intracellular channel protein in the HFS
group compared to Cont (p=0.008), as well as a 72.3% decrease in HFS+RSV
compared to Cont ( p=0.0051). PDQuest data from the protein spot identified as
chloride intracellular channel protein by MS/MS analysis showed a 98.7%
decrease in levels from the Cont diet to the HFS diet (p=0.0234), and a 62.77%
decrease in levels from the Cont diet to the HFS+RSV diet (p=0.0294). Figure 5
is the Western blot image of the samples after probing with a primary alpha-
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internexin antibody, whereas tubulin was the loading control. The HFS group
demonstrated only a trend (p=0.059) toward a decreasae compared to Cont
despite a 32.8% reduced levels of alpha-internexin. HFS+RSV had a 41.7%
increase in levels of alpha-internexin compared to the HFS group (p=0.0159) but
was not different from Cont.The variations in fold changes between the two
detection methods may be attributed to the sensitivity of the Sypro Ruby staining
method of the 2-D gels contrasted to the range limitations involved with the
chemiluminescent development of the 1-D Western blot. These validation
experiments support the findings in the proteomics identification of the main
proteins in the study.
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Figure 5.4.2: CLC-4 Western blot validation
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Figure 5.4.2b: AIN Western blot validation

5.5 DISCUSSION OF RESULTS
Discovery-based expression proteomics was used to compare the effects of
three experimentally controlled dietary conditions in adult male rhesus monkeys:
a standard healthy control diet, a Westernized diet high in fat and sugar, and the
HFS diet supplemented with RSV. Ten proteins were identified in the HFS
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groups with a significant differential expression when compared to Cont diet
monkeys. The functions of these proteins vary greatly but all can be considered
contributing to the proper functioning of biological systems such as metabolism,
structural integrity, neurotransmission, and cellular signaling. RSV’s greatest
effects reportedly occur within a metabolically impaired state such as obesity and
diabetes, while healthy individuals benefit less (Ghanim, Sia et al. 2010,
Timmers, Konings et al. 2011, Crandall, Oram et al. 2012, Marchal, Blanc et al.
2012, Yoshino, Conte et al. 2012). A recent study published by collaborators
using the monkeys from which our samples were derived measured the levels of
RSV in the CSF of HFS+R, but were unable to detect RSV in the Cont and HFS
groups demonstrating the efficacy of the RSV supplementation (Bernier, Wahl et
al. 2016). Moreover, they were able to measure SIRT1 and SIRT2 levels and
activity (via acetylated tubulin). While it was found that SIRT1 levels were
unchanged across the three groups, the HFS+R group had a significant reduction
in SIRT2 levels that accompanied an increase in expression of α-tubulin and a
reduction in the ratio of acetylated tubulin/total tubulin, of which the authors
suggest may be due to compensatory mechanisms of acetylation (Bernier, Wahl
et al. 2016).

Here, we identified a number of parietal lobe proteins of differential levels in
monkeys consuming an HFS diet for two years. In several, but not all cases RSV
supplementation was associated with a change in the expression profile
suggestive of improved function. Those proteins exhibiting level changes
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associated with treatment are classified here by cellular sub-systems and
discussed in that context. A graphical illustration of the protein and a primary
canonical function is provided in Figure 6.

Figure 5.5: Identified proteins and representative cellular responsibilities
(Permission Granted by Elsevier)

5.5.1.1 ENERGY
The production and maintenance of cellular stores of energy is a complex and
necessary function of all systems within an organism, however, the brain is
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unique in its energy consumption needs. The brain is a small fraction of the total
mass of an organism, yet it consumes upwards of 30% of all inspired oxygen and
20% of ingested glucose for its energy needs. This energy is used to maintain
neuronal cell resting potentials, neurotransmitter production and release, as well
as the propagation of action potentials, among other functions. Moreover, the
brain is highly dependent upon glucose for its functioning, and any severe
decrease in glucose metabolism may prove to be detrimental to the health of the
organism. Therefore, an analysis of proteomic changes to the levels of metabolic
enzymes as a function of diet could prove useful in understanding the effects of a
Western diet and/or resveratrol supplementation on the brain.
Pyruvate kinase was significantly decreased (0.11-fold) in the HFS group
compared to Cont. As glucose is the primary source of energy for the brain, we
posit that the observed decrease in these two glycolytic enzymes following two
years on HFS diet represent energy impairment imparted by the unhealthy diet.
Resveratrol supplementation to an HFS diet appeared to preferentially act on
ENO1 levels as alpha-enolase (ENO1) was 3.15-fold higher in the HFS+RSV
compared to HFS group. ENO1, is most commonly known for its role in glycolysis
in which it catalyzes the production of phosphoenolpyruvate from 2phosphoglycerate. A loss of glycolytic enzymes could potentially have a negative
effect on the efficiency of glucose utilization and thus, normal brain function.
However, ENO1 is a pleiotropic enzyme with many functions beyond glucose
metabolism. ENO1 has been shown to exhibit functions of a heat shock protein,
a hypoxic-stress protein, a neurotrophic factor, as well as a transcription
126

modulator (Butterfield and Lange 2009). Enolase has been found to be
compromised in several neurodegenerative diseases such as AD, Huntington’s
disease, and amyotrophic lateral sclerosis (Castegna, Aksenov et al. 2002,
Perluigi, Fai Poon et al. 2005, Perluigi, Poon et al. 2005).
BACH protein was 58.2-fold lower in the HFS monkey parietal lobe compared to
Cont. BACH cleaves acyl-CoA into coenzyme-A (CoASH) and the resultant fatty
acid. Fatty acids, acyl-CoA, and CoA-SH all serve diverse biological functions
important in processes such as ß-oxidation and metabolism in general, lipid
synthesis, gene regulation, cellular signaling, and enzymatic regulation.
Additionally, within the brain, they serve as an energy source, and in the process
of lipid synthesis and homeostasis, cellular signaling, enzyme regulation, vesicle
trafficking, and gene expression, bio-molecular trafficking, and ion flux (Hunt and
Alexson 2002, Yamada, Kuramochi et al. 2002, Yamada 2005, Hulbert,
Pamplona et al. 2007). BACH has been found to be crucial in preventing
neurotoxicity via dysregulation of fatty acid metabolism while also regulating cell
and membrane stability, potentially impacting the aging rate (Hulbert, Pamplona
et al. 2007, Ellis, Wong et al. 2013). BACH is more active in the brain than in any
other organ system and our data suggest that long-term consumption of an HFS
diet by a nonhuman primate may impair its expression levels. This finding may
have direct implications on healthy brain function as previous research has
indicated that functioning BACH provides protection from neurotoxicity (Yamada
2005).
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5.5.1.2 STRUCTURE
Microtubules are structural protein complexes that provide structural integrity to
the cell, as well as roles in cellular processes such as cell division, ciliary/flagellar
movement, and intracellular transport. Microtubules are composed of alpha- and
beta-tubulin that self-assemble into large polymers. However, due to rapidly
changing complex needs of the cell, microtubules must be dynamic in their
construction and deconstruction. Stathmin is a key protein in the regulation of
microtubule assembly and disassembly and impedes formation of microtubules
through the sequestration of soluble tubulin into T2S complexes (Curmi, Gavet et
al. 1999). Therefore, the levels of stathmin may directly affect microtubule
turnover and dynamics. Moreover, an overexpression of stathmin is found to be
present in various forms of cancers and in AD progression, while also being
positively correlated to telomere shortening (Belletti and Baldassarre 2011, Ahn,
Yoo et al. 2014). In the current study, monkeys fed HFS+RSV have a 0.69-fold
decrease of stathmin compared to HFS fed monkeys. This decrease in stathmin
may allow for increased microtubule formation and stability, consistent with more
efficient intracellular transport of vesicles and mitochondria.
Collapsin response mediator protein-2 (CRMP-2; also called
dihydropyrimidinase-related protein 2 (DRP-2)) is important in the proper
functioning of neurons, and its aberrant expression and/or inactivity has been
implicated in neurodegenerative diseases such as AD (Butterfield, Perluigi et al.
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2006, Hensley, Venkova et al. 2011). The primary roles of CRMP-2 are control of
the dynamic stability of microtubules, neural differentiation and specification for
axons and dendrites, the proper outgrowth/retraction of neurites,
neurotransmitter release, indirect control of axonal transport, and calcium
homeostasis (Goshima, Nakamura et al. 1995, Inagaki, Chihara et al. 2001,
Yoshimura, Kawano et al. 2005, Hensley, Christov et al. 2010, Hensley, Venkova
et al. 2011). CRMP-2 is the only CRMP to be maintained at high levels in adult
neurons and is mostly expressed in areas requiring high degrees of plasticity
such as the hippocampus, cerebellum, and olfactory bulb (Charrier, Reibel et al.
2003). Within the neuron, CRMP-2 is found within the growth cone and
synapses, indicative of its function (Chu, Wang et al. 2010). Here, we showed
that levels of CRMP-2 are significantly reduced in HFS and HFS+RSV compared
to Cont at 0.079-fold and 0.011-fold, respectively. These data indicate that
CRMP-2 may be decreased in response to a HFS, unhealthy diet and RSV was
not protective in monkeys. The implementations of this reduced level is that
neuritic extensions would be shorter, thereby making fewer synaptic connections.
HFS could therefore lead to detrimental cognitive changes.
Oligodendrocytes are one of the major cell types of the CNS as a component of
the myelin sheath, wrapping around the adjacent neuronal axons to allow
saltatory impulse propagation. Oligodendrocytes are associated with 2,3-cyclic
nucleotide 3-phosphodiesterase (CNP), which plays an important, albeit not well
understood, role in myelin formation. CNP is located in non-compacted myelin
regions while absent in compacted sheath (Braun, Sandillon et al. 1988, Trapp,
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Bernier et al. 1988). Lappe-Seifke et al. silenced the Cnp1gene in mice, which
resulted in fully myelinated offspring, but with severe axonal swelling and death
by 12 months (Lappe-Siefke, Goebbels et al. 2003). In Cnp-1 null mice, the
absence of CNP led to disorganized oligodendroglial paranodes and altered
communication between neuronal axons and oligodendrocytes and
consequential neurodegeneration (Rasband, Tayler et al. 2005). In our
HFS+RSV fed nonhuman primates, CNP was down regulated 0.492-fold
compared to the HFS-fed group indicating that RSV supplementation appears to
have a detrimental impact on CNP performance.

Vacuolar H+-ATPases (V-Type ATPase) have a structure and mechanistic action
similar to that of F-Type ATPases, which are found in the inner mitochondrial
membrane and used for oxidative phosphorylation, yet the ultimate function they
perform differs. While F-Type ATPases use proton gradients to drive ATP
production, V-Type ATPases use ATP to drive proton gradients (Nishi and
Forgac 2002). The establishment of an electrochemical proton gradient across a
lipid bilayer is used in a variety of processes from the acidification of lysosomal
luminal space, to the packaging of neurotransmitters into synaptic vesicles and
endocytic transportation (Maxson and Grinstein 2014). For instance, the
environment of an endocytic vesicular lumen made acidic in comparison to the
surrounding cytosol by V-Type ATPases allows for the dissociation of ligands
and receptors for recycling of the components (Maxfield and McGraw 2004). In
regards to protein degradation and turnover, V-Type ATPases play an important
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role in the autophagic pathway in direct and possibly indirect manners. First, VType ATPases directly acidify the lysosomal luminal space to a pH of around 4.5
in order to provide an optimal environment for lysosomal protease functioning
(Huynh and Grinstein 2007, Maxson and Grinstein 2014). A less well
characterized function of V-Type ATPases in regards to induction of autophagy is
their proposed ability to activate lysosomal bound mTORC1, a required step for
mTORC1 activation. It is hypothesized that due to V-Type ATPases interaction
with both mTORC1 and Ragulator, that V-Type ATPases may sense levels of
available amino acids and convey that information to mTORC1 (Zoncu, BarPeled et al. 2011, Bar-Peled, Schweitzer et al. 2012, Xu, Parmar et al. 2012). In
this study, we found a significant increase in isoform 3 of V-Type proton ATPase
subunit E-1 protein level (4.67-fold) in the HFS+RSV group compared to Cont.
We hypothesize that an increase in V-Type ATPase levels with RSV
supplementation represents the cellular attempt at an autophagy response as
needed while preserving the necessary brain functions such as neurotransmitter
processing and lysosomal efficacy.

5.5.1.3 SIGNALING
One method of signal transduction is through the activation of transmembrane Gprotein coupled receptors (GPCRs). GPCRs participate in many signaling and
physiological functions such as neurotransmission, peptide hormone signaling,
vision, taste, and smell (Rosenbaum, Rasmussen et al. 2009). GPCRs have a
small G-protein docked to the intracellular side of the receptor, which upon
131

receptor activation is itself activated by the replacement of GDP with GTP in its
regulatory site causing the G-protein to split into Gα and Gβγ subunits. Upon
activation of the Gα-subunit by GTP, the Gα-subunit is free to activate
downstream effectors such as adenylate cyclase (AC), a signal amplifying
enzyme that creates the secondary messenger cyclic-AMP (cAMP) from ATP.
Following this process, the Gα-subunit’s GTPase activity slowly turns the GTP
back to GDP, deactivating itself to start the cycle anew. Guanine nucleotidebinding protein (Gi/Gs/Gt)-1 (GNB1), the β subunit, is responsible for the GTPase
activity, which allows for the activation of the G-protein, guanine nucleotide
exchange, and also for downstream signaling of the Gβγ complex (Oldham and
Hamm 2008). In the present study, the HFS+RSV diet led to an increase in
GNB1 by 3.61-fold over that of the brain of monkeys fed the HFS diet alone,
whereas GNB1 was found to have a significant decrease in levels (0.27-fold) in
the HFS compared to Cont. The results suggest that while the HFS diet alone
may have a detrimental role in levels of GNB1, RSV may attenuate that loss,
suggestive of a protective effect. GNB1 is necessary for the direct activation of
downstream effects such as phosphoinositide-3-kinase, phospholipase-C
isoforms, and ion channels, while indirectly participating in all Gα activities due to
their regulatory nature over the Gα subunit (Cabrera-Vera, Vanhauwe et al.
2003). Here, our proteomics studies are consistent with the notion that addition of
RSV to a HFS diet promotes cellular signaling in brain that is diminished in brain
of HFS-fed monkey group.
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Glutamine synthetase is a key protein of astrocytes in the brain as it is involved in
the glutamate-shuttle and subsequent conversion of the neurotransmitter
glutamate to inactive glutamine prior to being translocated back to the neuron.
The glutamate shuttle is important for the health of the neuron as glutamate is an
excitatory neurotransmitter which if left in the synapse and not converted to
glutamine may cause excitotoxicity and subsequently neuron death through
calcium dysregulation (Takahashi, Foster et al. 2015). However, the glutamine
shuttle is not solely responsible for glutamate availability at the synapse (Danbolt
2001). We report that glutamine synthetase has significantly reduced levels
(0.76-fold) in the HFS+RSV when compared to Cont, and decreased but not
significantly decreased levels in HFS compared to Cont suggesting that the HFS
diet depressed levels of glutamine synthetase that are not recovered, and
perhaps even exacerbated, with RSV supplementation. It has been suggested in
a 3x-TG-AD mouse model that depression of glutamine synthetase levels may
lead to errant glutamate homeostasis and regulation as well as memory and
cognitive impairment that may be attributed to failures in synaptic connectivity, all
of which are apparent in human AD (Kulijewicz-Nawrot, Sykova et al. 2013).

Chloride intracellular channel protein 4 (CLC-4) is a multifunctional protein
predominantly known for its role as a chloride channel, as its name implies.
However, CLCs have recently been shown to participate in other physiological
roles such as a mediator of apoptosis in which this protein is translocated to the
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nucleus (Ryu, Peixoto et al. 2010, Qian, Du et al. 2011). The suppression of
CLC-4 with siRNA is reported to be involved in enhanced hydrogen peroxide
mediated apoptotic activation (Xu, Kang et al. 2013), whereas others showed
siRNA interference of CLC-4 enhanced TNFα-mediated apoptosis in a p53independent manner (Suh, Mutoh et al. 2005). However, the role of CLC-4 in
apoptosis is complex, as demonstrated by its ability to be highly apoptotic in and
of itself when Apaf1 is deleted, inhibiting the mitochondrial apoptotic pathway
(Suh, Mutoh et al. 2004). Here, we show a significant decrease in CLC-4 in both
the HFS vs Cont and HFS+RSV vs Cont groups with 0.28-fold and 0.37-fold
protein level of control, respectively. We posit that this decrease in CLC-4 levels
in both unhealthy diet groups is indicative of potential apoptotic regulation, and
as oxidative stress is a hallmark of both diabetes and AD, it is possible that
hydrogen peroxide mediated apoptosis is in part responsible for cognitive
deficiencies, though follow-up research is needed to clarify this speculation.

SH3 domain-binding glutamic acid-rich-like protein (SH3BGRL) is homologous to
glutaredoxin 1 in E. coli, an oxioreductase, thought to belong to the thioredoxinlike protein family (Egeo, Mazzocco et al. 1998). SH3BGRL2, a homologue of the
SH3BGRL family, was later identified and shown to have a high similarity to other
SH3BGRL homologue N-terminal region (Mazzocco, Maffei et al. 2002). While
SH3BGRL proteins may belong to the thioredoxin-like super family of proteins, all
homologues are devoid of the CXXC motif indicating that they most likely do not
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have any thioredoxin-like enzymatic activity (Mazzocco, Maffei et al. 2002).
However, due to its shared homology, specifically to that of glutaredoxin, it is
possible that SH3BGRL proteins participate in the regulation of redox sensitive
proteins, possibly through the action of its PICOT homology domain, allowing it to
engage in protein-protein interactions hinting at its role as a protein regulator
(Mazzocco, Maffei et al. 2002). Research supports the notion of SH3BGRL
protein SH3BGRL3 as acting as an indirect inhibitor of TNF-α through the
activation of NF-κB by way of its PICOT homology (Witte, Villalba et al. 2000, Xu,
Zheng et al. 2005). Here we observed a decreased level of SH3BGRL2 (0.69fold) in HFS+RSV diet fed monkeys vs Cont monkeys. As both SH3GBRL2/3
share similar PICOT homology, it is possible that RSV supplementation in an
HFS diet modulates the inflammatory response through SH3BGRL2/3 decrease
of active TNF-α and subsequently modulating the inflammatory response, though
this speculation needs further study to confirm.
5.6 CONCLUSION:
Using proteomics, we have identified a number of proteins with differential
expression in the parietal lobule of adult male rhesus monkeys fed Cont, HFS or
HFS+RSV diets over a duration of two years. Our findings suggest potential
improvements in energy metabolism, efficiency of canonical cell signaling
pathways, and neurotransmission with RSV supplementation to an HFS diet. In
contrast, some brain protein levels such as CNP and glutamine synthetase may
not be attenuated by RSV supplementation of an unhealthy diet. While it has
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been shown in other studies that resveratrol addition to a normal diet may not
provide significant benefits to healthy individuals, it has been observed that
resveratrol does lead to marked improvement in individuals already exhibiting
signs of metabolic syndrome (Timmers, Konings et al. 2011, Crandall, Oram et
al. 2012, Yoshino, Conte et al. 2012). Our studies contribute to the understanding
of the changes occurring in the proteome of the dietary-impaired parietal lobule
of non-human primates given resveratrol supplementation.
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CHAPTER 6: CONCLUSIONS AND FUTURE STUDIES
The Pin1 overexpression study yielded a number of interesting proteins with
differential expressions from a wide range of cellular processes including
structure (Neurofilament-light and Actin Related Protein 3), signaling
(Phosphatidylethanolamine-binding protein 1, Myc box-dependent-interacting
protein 1, Growth factor receptor-bound protein 2 and Cofilin-1), immune
response (Immunity related GTPase family Q protein and Dopachrome
decarboxylase) and finally energy production and utilization (Glyceraldehyde-3phosphate dehydrogenase and Carbonic Anhydrase). While Pin1 overexpression
may be well intended, there are possibilities that it could be a detriment to the
organism as a whole due to Pin1 being highly involved in many signaling
processes, such as cell signaling and the possibility that overexpression could
lead to cancer and has been noted previously (Xu and Etzkorn 2009). While the
use of Pin1 overexpression in humans likely not to be used due to possible
ethical concerns, any study using differential levels of such ubiquitous signaling
proteins should use caution. Therefore, if this study were to be elaborated upon
and extended, the effects upon oncogenesis should be taken into account. This
is especially important and relatable due to the fact that the link between AD and
the cell cycle possibly initiating in post-mitotic neurons has not been fully
established (van Leeuwen and Hoozemans 2015).

In regards to the intra-nasal insulin administration study, while not much oxidative
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stress information was able to be garnered from the animals used, a small but
significant decrease in protein carbonyls in APP/PS1 and dbdbxAPP/PS1 mouse
models was found. Also using expression proteomics, a number of proteins from
different cellular processes were found to be differentially expressed in a number
of comparisons as a function of treatment including energy and metabolism (ATP
synthase subunit d, mitochondrial), structure (Stathmin), molecular recycling and
management (Proteasome subunit alpha type-5, Transitional endoplasmic
reticulum ATPase, and Hypoxathine-guanine phosphoribosyltransferase),
signaling (Growth factor receptor-bound protein 2 and Voltage-dependent anion
selective channel protein 1) and oxidative stress management (Superoxide
dismutase 1).

This study shows promise, however, fell victim to low sample sizes due to the
fact that too many animals died during the course of the treatment. Our study
took place over the course of two months, from 8 months to 10 months of age.
These mice, particularly the dbdbxAPP/PS1 mice, have drastically shortened
lifespans and many health complications. It would have been beneficial to
shorten the length of treatment and begin treatment at an early time frame in
order to preserve the sample size needed for such an adventurous study while
also yielding interesting results in regards to the action of insulin on the disease
states utilized. If given more funding and time, I would do just this and use the
additional sample size to verify the oxidative stress measures within this
dissertation that were called into question due to sample standard deviation.
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Moreover, delving into the actual signaling components behind the scenes of
protein level changes would yield quite a bit of interesting information and
possibly new leads as to the method of action of intra-nasal insulin in the
prevention of cognitive dysfunction. For example, due to IRS1 interaction with
BVR-A, and the pleiotropic nature of BVR-A in signaling and oxidative stress
prevention through bilirubin production, BVR-A activity and levels in each group
as a function of insulin administration.

The resveratrol study also yielded proteins from a wide range of cellular
processes including energy and metabolism (Pyruvate Kinase, Enolase, and
BACH), structure (Stathmin, Collapsin response mediator protein-2, 2,3-cyclic
nucleotide 3-phosphodiesterase, and Vacuolar H+-ATPase) and signaling
(Enolase, Guanine nucleotide binding protein-1, Glutamine Synthetase, Chloride
Intracellular channel protein-4, and SH3 domain-binding glutamic acid-rich-like
protein). These proteins and their differential expression in regards to diet and
supplementation yielded information towards to effects of resveratrol on protein
expression in a Western-diet as well as that of a Western-diet over a normal diet.
Because of the nature of the study and the cost of raising non-human primates,
the samples given were extremely small and therefore we had to make the
decision of whether to proceed with oxidative stress measures or expression
proteomics and decided that expression proteomics would yield the most data at
the cost of sample. Therefore, the next step should more sample be provided
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would be to use that sample for oxidative stress measure on the parietal lobe of
the Rhesus monkeys.
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Appendix A
DATA TO SUPPLEMENT TABLES AND FIGURES

Average
Pin1/Tubulin Avgavg

%Control Avg

GFP

10.727

154.8301

GFP

5.716808

82.51461

GFP

4.666989

67.36185

GFP

5.692567

82.16471

GFP

6.086991

87.85771

GFP

8.679073

125.271

6.928238

Stdev

SEM

100 33.11038 14.80741

Pin1

31.81288

459.1771

Pin1

13.93558

201.1418

Pin1

10.88674

157.1358

Pin1

36.72627

530.0954

Pin1

26.79006

386.6793

Pin1

35.92827

518.5772

Pin1

26.34543

380.2617

Pin1

39.99102

577.2178

Pin1

0.046643

0.673236

Qtest
401.2858 153.5182 68.65543

t‐test

0.000532

1 Month GFP v Pin1: Pin1 Expression
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Average
Pin1/Tubulin Avgavg

%Control Avg

GFP

5.830565

87.8494

GFP

6.606754

99.54428

GFP

6.483299

97.68417

GFP

6.589165

99.27926

GFP

5.488294

82.69239

GFP

6.46932

97.47356

GFP

7.463709

112.4561

GFP

8.164897

123.0209
6.637001

Stdev

SEM

100 12.78827 5.719086

Pin1

12.75024

192.1085

Pin1

18.51177

278.9177

Pin1

19.97717

300.997

Pin1

13.27667

200.0402

Pin1

29.31275

441.6565

Pin1

16.18672

243.886

Pin1

18.49807

278.7113

Pin1

23.49671

354.026
286.2929 82.08208 36.70822
t‐test

1.82E‐05

6 Month GFP v Pin1: Pin1 Expression
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Average
Pin/Tubulin Avgavg

%Control Avg

GFP

3.237865

74.30192

GFP

3.895522

89.39373

GFP

3.24245

74.40714

GFP

3.258242

74.76954

GFP

3.643145

83.60221

GFP

5.314786

121.9627

GFP

3.500161

80.32104

GFP

4.380138

100.5146

GFP

8.74711

200.7271
4.357713

Stdev

SEM

100 40.84907 18.26826

Pin1

14.21971

326.3112

Pin1

16.88588

387.494

Pin1

16.77877

385.0362

Pin1

14.60185

335.0805

358.4805 32.29763 14.44394
t‐test

2.55E‐07

9 Month GFP v Pin1: Pin1 Expression
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Average
Pin1/Tubulin Avgavg

%Control Avg

GFP

2.054185

133.6256

GFP

1.722488

112.0486

GFP

1.282583

83.43263

GFP

2.008937

130.6822

GFP

1.3437

87.40831

GFP

0.709421

46.14816

GFP

1.434925

93.34249

GFP

1.741909

113.3119
1.537268

Stdev

SEM

100 28.71493 12.84171

Pin1

18.34401

1193.286

Pin1

5.636706

366.6703

Pin1

10.73396

698.249

Pin1

8.448186

549.5583

Pin1

13.32361

866.7071

734.8941 315.7447 141.2053
t‐test

0.000118

12 Month GFP v Pin1: Pin1 Expression
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Average

Avgavg

%Control Avg

Saline

3464714

84.89407

Saline

3213446

78.73737

Saline

4409173

108.0356

Saline

2589575

63.45098

Saline

4353913

106.6816

Saline

6456504

158.2003

4081221

Stdev

SEM

100 33.20425 14.84939

Insulin

3310523

81.116

Insulin

2812570

68.91491

Insulin

6236496

152.8096

Insulin

6160327

150.9433

113.4459 44.66087 19.97295
0.597669
4629979

Saline v Insulin: dbdbxAPP/PS1 HNE
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Average

Avgavg

%Control Avg

Saline

6900897

99.46383

Saline

5561228

80.15494

Saline

6665079

96.06493

Saline

3606854

51.98621

Saline

8534786

123.0134

Saline

10359740

149.3167

6938097

Stdev

SEM

100 33.69474 15.06875

Insulin

7763934

111.9029

Insulin

7274736

104.852

Insulin

9799472

141.2415

Insulin

7413528

106.8525

116.2122 16.94789 7.579327
0.405267
8062917

Saline v Insulin: dbdbxAPP/PS1 3NT
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Average

Avgavg

%Control Avg

Saline

17719200

102.8958

Saline

16512450

95.88816

Saline

17866350

103.7503

Saline

17270900

100.2925

Saline

16733750

97.17326

Saline

9389800

Stdev

SEM

54.52678 Qtest

17220530

100 3.443599 1.540024

Insulin

15983050

92.81393

Insulin

15516050

90.10205

Insulin

15386850

89.35178

Insulin

15692900

91.12902

90.84919 1.498772 0.670271
0.001746
15644713

Saline v Insulin: dbdbxAPP/PS1 PC TRIAL 1
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Average

Avgavg

%Control Avg

Saline

16112372

94.26506

Saline

17415012

101.8861

Saline

18480890

108.122

Saline

16752786

98.01179

Saline

16702059

97.71501

Saline

8960142

Stdev

SEM

52.4211 Qtest

17092624

100

Insulin

11722655

68.58312

Insulin

15474566

90.53359

Insulin

16094834

94.16245

Insulin

16142120

94.4391

5.28177 2.362079

86.92956 12.35973 5.527439
0.067663

Saline v Insulin: dbdbxAPP/PS1 PC TRIAL 2
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Average

Avgavg

%Control Avg

Saline

2978910

78.81728

Saline

4591944

121.4956

Saline

3402972

90.03729

Saline

3870558

102.4089

Saline

3370950

89.19004

Saline

4461750

118.0509

3779514

Stdev

SEM

100 17.07933 7.638109

Insulin

3198798

84.63517

Insulin

2743524

72.58933

Insulin

2197800

58.15033

Insulin

4339980

114.829

82.55097 24.08903 10.77294
0.213436
3120026

Saline v Insulin: dbdb HNE
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Average

Avgavg

%Control Avg

Saline

11894800

89.78454

Saline

14740972

111.2681

Saline

12312166

92.93491

Saline

13194910

99.59805

Saline

12726912

96.0655

Saline

14619207

110.349

13248161

Stdev

SEM

100 8.988694 4.019866

Insulin

10467293

79.0094

Insulin

13454355

101.5564

Insulin

14471112

109.2311

Insulin

14956270

112.8932

100.6725 15.19502 6.795418
0.93128
13337257

Saline v Insulin: dbdb 3NT

169

Avgavg

%Control Avg

Saline

11443848

89.99145

Saline

12383162

97.37797

Saline

13562415

106.6513

Saline

13098983

103.007

Saline

11714813

92.12225

Saline

14096346

110.85

12716594

Stdev

SEM

100 8.247542 3.688413

Insulin

13490304

106.0843

Insulin

14309196

112.5238

Insulin

13468374

105.9118

Insulin

13132910

103.2738

106.9484 3.933157 1.758961
0.16006

Saline v Insulin: dbdb PC
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Average

Avgavg

%Control Avg

Saline

3576617

79.67763

Saline

4917862

109.557

Saline

5299308

118.0546

Saline

4936665

109.9759

Saline

3713848

82.73477

4488860

Stdev

SEM

100 17.52079 7.835537

Insulin

3056851

68.0986

Insulin

3784426

84.30705

Insulin

4217537

93.95564

Insulin

4188489

93.30852

Insulin

3804264

84.74899
84.88376 10.43274 4.665662
0.135989
3810313

Saline v Insulin: APP/PS1 HNE
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Average

Avgavg

%Control Avg

Saline

5763713

61.80467

Saline

7277970

78.04216

Saline

7153230

76.70456

Saline

15336458

164.4539

Saline

11097083

118.9948

9325691

Stdev

SEM

100 41.82944 18.70669

Insulin

6867315

73.63868

Insulin

5734365

61.48998

Insulin

5489925

58.86883

Insulin

5540168

59.40758

Insulin

9006638

96.57877
69.99677 16.03273 7.170055
0.172604
6527682

Saline v Insulin: APP/PS1 3NT
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Average

Avgavg

%Control Avg

Saline

13504150

99.19009

Saline

14241480

104.6059

Saline

14251655

104.6806

Saline

13492985

99.10809

Saline

12581800

92.41529

13614414

Stdev

SEM

100 5.052275 2.259446

Insulin

10953415

80.45455

Insulin

12953435

95.14501

Insulin

12673925

93.09196

Insulin

12811645

94.10354

Insulin

12907620

94.80849
91.52071

6.23588

0.045783

Saline v Insulin: APP/PS1 PC TRIAL 1
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2.78877

Average

Avgavg

%Control Avg

Saline

11498630

96.97308

Saline

12995070

109.5932

Saline

11663685

98.36506

Saline

11108955

93.68677

Saline

12021405

101.3819

11857549

Stdev

100 6.033896

Insulin

10442410

88.0655

Insulin

10786490

90.96728

Insulin

11016390

92.90613

Insulin

11841335

99.86326

Insulin

10406550

87.76308

SEM

2.69844

91.91305 4.927282 2.203547
0.048823

Saline vs Insulin: APP/PS1 PC TRIAL 2
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Avgavg

%Control Avg

Saline

3165812

71.47964

Saline

2532140

57.17221

Saline

6247748

141.0655

Saline

5770180

130.2827

4428970

Stdev

SEM

100 41.83716 18.71015

Insulin

3746132

84.58246

Insulin

6198348

139.9501

Insulin

3239496

73.14333

Insulin

6608784

149.2172

Insulin

4726176

106.7105

Insulin

4369144

98.64921
108.7088 30.22952 13.51905
0.710215

Saline v Insulin: WT HNE
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Average

Avgavg

%Control Avg

Saline

4838575.5

65.80895

Saline

3711708

50.48255

Saline

10406583

141.5388

Saline

10452964.5

142.1697

7352458

Stdev

SEM

100 48.73315 21.79413

Insulin

4959108

67.4483

Insulin

7801992

106.1141

Insulin

4714132.5

64.11642

Insulin

7797240

106.0494

Insulin

7065580.5

96.09821

Insulin

6040237.5

82.15263
86.99651 18.65706 8.343693
0.561845

Saline v Insulin: WT 3NT
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Average

Avgavg

%Control Avg

Saline

11194345

98.95899

Saline

10410351

92.02841

Saline

12108120

107.0368

Saline

11535605

101.9758

11312105

Stdev

SEM

100 6.272973 2.805359

Insulin

10185199

90.03805

Insulin

11704258

103.4667

Insulin

10854385

95.95371

Insulin

12125183

107.1877

Insulin

10949926

96.7983

Insulin

12090887

106.8845
100.0548 6.883641 3.078458
0.990141

Saline v Insulin: WT PC
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